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ABSTRACT 
 
 
Introduction 
Hypertrophic cardiomyopathy (HCM) is an inherited myocardial disease associated with 
atrial fibrillation (AF) and thromboembolism (TE), which are related to adverse clinical 
outcomes and reduced survival. Current ESC and ACCF/AHA guidelines recommend 
anticoagulation in all patients with HCM and atrial fibrillation but the absolute risk of 
thromboembolism in patients with and without documented AF is unclear. The primary 
aim of this study was to derive and validate a model for estimating the risk of TE in 
HCM. Analyses were performed to determine predictors of AF and TE. Exploratory 
analyses assessed the performance of the CHA2DS2-VASc score and outcome with 
vitamin K antagonists (VKA). A further aim was to investigate the effect of AF on 
mortality and the efficacy of antiarrhythmic therapy in the development of AF.  
 
Objectives 
The aims of the thesis were to:  
a) Systematic review of the literature on atrial fibrillation and thromboembolism in 
patients with HCM and meta-analyse prevalence and incidence of atrial fibrillation and 
thromboembolism 
b) Assess prevalence, incidence and predictors of AF in a large multicentre cohort 
c) Investigate the effect of AF on mortality 
d) Assess clinical predictors of thromboembolism and derive and validate a risk model 
for estimating the risk of thromboembolism in patients with and without documented 
atrial arrhythmia 
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e) Assess the performance of the CHA2DS2-VASc score in this population  
f) Assess the effect of therapy with vitamin K antagonists (VKA) in patients with AF and 
their bleeding risk (HAS-BLED score) 
g) Investigate effect of antiarrhythmic therapy on the development of AF  
 
Methods 
Retrospective, observational cohort studies. The primary outcomes were a 
thromboembolic event defined as a composite of cerebrovascular accident (CVA), 
transient ischaemic attack (TIA) or systemic peripheral embolus as defined in the 
CHA2DS2-VASc score and atrial fibrillation, which was defined as paroxysmal, 
permanent or persistent AF detected on ECG, Holter monitoring or device interrogation. 
The secondary outcome was all-cause and cardiovascular mortality (defined as sudden 
cardiac death, heart failure related death, stroke related death and other cardiac death). 
Results 
a) Systematic review of the literature on atrial fibrillation and thromboembolism in 
patients with hypertrophic cardiomyopathy 
The meta-analysis of a population of 7381 patients revealed an overall AF prevalence of 
22.45% (95% CI 20.13% to 24.77%), I2=78.9% (p<0.001). Overall prevalence of 
thromboembolism in HCM patients with AF was 27.09% (95% CI 20.94% to 33.25%), 
I2=61.4% (p<0.01). Overall AF incidence was 3.08% per 100 patients per year (95% CI 
2.63% to 3.54%, I2=86.5%, p<0.001) and incidence of thromboembolism in HCM 
patients with AF was 3.75% per 100 patients per year (95% CI 2.88% to 4.61%), 
I2=37.9% (p=0.1).  
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Left atrial (LA) dimension and age were common predictors for AF and 
thromboembolism. Meta-analysis revealed an LA diameter of 38.03 mm (95% CI 34.62-
41.44) in SR and 45.37 mm (95% CI 41.64-49.04) in AF. There were no RCTs of 
therapy; anticoagulation was associated with lower stroke incidence but data on other 
interventions were limited and contradictory. 
b) Assess prevalence, incidence and predictors of AF in a large multicentre cohort 
c) Investigate the effect of AF on mortality 
Of 4248 HCM patients 740 (17.4%) patients reached the primary endpoint of AF within 
10 years from first evaluation. Multivariable Cox regression revealed an association 
between AF and the following: female sex, LA diameter, NYHA class II, NYHA class III 
and IV, hypertension and vascular disease. The incidence of cardiovascular death was 
4.92% in the sinus rhythm (SR) group and 10.9% in the AF group (difference in 
proportions = 5.9%; 95% CI= [4.1%-7.8%]). The incidence of non-cardiovascular death 
was 3.2% in the SR group and 5.9% in the AF group (difference in proportions= 2.8%; 
95% CI= [0.1%- 4.2%]). 
 
d) Assess clinical predictors of thromboembolism and derive and validate a risk model 
for estimating the risk of thromboembolism in patients with and without documented 
atrial arrhythmia 
e) Assess the performance of the CHA2DS2-VASc score in this population  
Of 4821 HCM patients in the thromboembolism cohort 172 (3.6%) reached the primary 
endpoint within 10 years. Cox regression revealed an association between TE and age, 
AF, the interaction between age and AF, TE prior to first evaluation, NYHA class, LA 
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diameter, vascular disease and maximal LV wall thickness. There was a curvilinear 
relation between LA size and TE risk. The model predicted TE with a C-index of 0.75 
(95% CI: 0.70, 0.80) and the D-statistic was 1.30 (95% CI: 1.05, 1.56). 27.5% of 
patients had a CHA2DS2-VASc score of 0 of whom 9.8% developed TE during follow up.  
f) Assess the effect of therapy with vitamin K antagonists (VKA) in patients with AF and 
their bleeding risk (HAS-BLED score) 
g) Investigate effect of antiarrhythmic therapy on the development of AF  
VKA treatment was associated with a 54.8% (CI 31%-97%, p=0.037) relative risk 
reduction in HCM patients with AF. Calculation of the HAS-BLED score in a population 
of 536 patients with HCM and AF revealed a score of 0-2 in 500 patients (93.3%) with a 
score of 3-5 in 36 patients (6.7%). 
An intention to treat analysis of β-blockers, calcium channel antagonists, disopyramide 
and amiodarone at baseline evaluation did not show a significant preventative effect on 
AF during follow up.  
Conclusions 
The literature review suggests that AF is common in HCM and associated with high 
thromboembolic risk. LA dimension and age are independently associated with AF but 
the existing literature is insufficient to create robust clinical tools to predict AF or 
thromboembolism. Most data suggest that AF patients should be anticoagulated. 
Our study shows that the risk of TE and AF in HCM patients can be identified using a 
small number of readily available clinical features. This study confirms that AF is 
associated with a poor prognosis in HCM. LA size, in particular, should be monitored 
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closely and the assessment and treatment of conventional vascular risk factors should 
be routine practice in older patients. Exploratory analyses show for the first time 
evidence for a reduction of TE with VKA treatment. The CHA2DS2-VASc score performs 
poorly in patients with HCM and should not be used to assess TE risk in this population. 
There is no evidence for the efficacy of antiarrhythmic therapy in development of atrial 
arrhythmia. 
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1 INTRODUCTION 
 
Hypertrophic cardiomyopathy (HCM) is a common genetic disorder of the heart muscle. It 
occurs in 1 in every 500 adults. In most individuals, it is inherited as an autosomal 
dominant trait caused by mutations in cardiac sarcomere protein genes and is associated 
with an increased risk of sudden cardiac death, stroke, long-term morbidity from 
progressive ventricular dysfunction and atrial and ventricular arrhythmias 1-3. The 
histological hallmark of HCM consists of myocyte disarray, fibrosis and small vessel 
disease 4. The hypertrophy is asymmetric in the majority of cases, but apical and 
concentric hypertrophy have also been described. A proportion of patients exhibit left 
ventricular outflow tract obstruction, systolic anterior motion of the mitral valve, which is 
associated with varying degrees of mitral regurgitation 5. 
A physician from Geneva, Theophile Bonet (1620–1689) described cardiomegaly as a 
heart ‘larger than that of any bullock’ in a coachman who died suddenly 6. William Harvey 
is also known to have described a patient with probable LVOT obstruction and symptoms 
of palpitations and chest pain 7. Giovanni Maria Lancisi (1654–1720), a physician to Pope 
Clement XI, described deaths due to hypertrophy, dilatation and valve defects on 
autopsies of patients with sudden death 8. Later Alfred Vulpian a physician and 
neurologist, coined the term ‘‘subaortic stricture’’ 9. Two of his interns Hallopeau and 
Liouville then proposed the term “subaortic stenosis” 10-12. Schmincke a German 
pathologist  described left ventricular hypertrophy in the absence of  physical exertion, 
renal or vascular disease 13. Brock published on functional obstruction of the left ventricle 
and Teare first described the pathology of asymmetric hypertrophy of the heart in modern 
times 14. Teare, who worked as a pathologist at St George’s hospital reported on eight 
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patients with sudden cardiac death and  also described ‘bizarre arrangements of bundles 
of muscle fibres running in diverse directions and separated by connective tissue and 
clefts’ 15. Three of the patients presented with palpitation as early symptom and were 
found to be in atrial fibrillation.  
Already since these times it has become clear that atrial fibrillation and stroke are common 
in HCM with significant impact on morbidity and mortality 16. Further information on 
prevalence, incidence and predictors of AF and thromboembolism in addition to 
identification of high risk patients is therefore of clinical importance to guide medical 
therapy and particularly anticoagulation. 
 
1.1 HCM: Definition and diagnostic criteria 
HCM is defined as left ventricular hypertrophy in the absence of abnormal loading 
conditions, such as hypertension and valve disease 1-3;17-19. The diagnosis relies on 
morphological assessment mostly by echocardiography and cardiac MRI with a maximal 
wall thickness of greater or equal to 15mm as usual diagnostic criteria for HCM in adults 
3;17. Familial hypertrophic cardiomyopathy is characterised by an autosomal dominant 
pattern of inheritance. First degree relatives of an individual with HCM therefore have a 
50% probability of being a carrier of the genetic mutation. Often mutation carriers will not 
fulfil the diagnostic criteria due to incomplete penetrance and expression. In these 
individuals minor abnormalities on electrocardiography and echocardiography reflect 
expression of a pathogenic gene mutation in these individuals 20. This disparity between 
affected and unaffected family members has several important implication, such as 
genetic testing, counselling and psychosocial factors. McKenna et al. therefore propose 
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major and minor criteria for the diagnosis of HCM in first degree family members. These 
criteria include echocardiography measurement, such as left ventricular wall thickness and 
systolic anterior motion of the mitral valve and also electrocardiography characteristics 20. 
1.2 Epidemiology 
Several methodologically diverse studies across the world suggest a prevalence of 
unexplained increase in LV thickness in the range of 0.02–0.23% in adults. The 
prevalence appears similar across different racial groups 1;21-25. An American study of 
4111 young patients selected from the general population revealed evidence of HCM in 
7 subjects (0.17%) on the basis of identification of a hypertrophied, non-dilated left 
ventricle and a MWT of 15 mm. Prevalence was higher in men than women 
(0.26:0.09%) 1. This male preponderance is common in most studies and remains 
unexplained, and might reflect study bias secondary to screening. Genetic and 
hormonal influences could be important as well 3. A further study from the US of 714 
consecutively studied outpatients referred for echocardiography HCM was present in 4 
patients (0.5%). This cohort of patients was older with ages between 50 to 69 years 26. 
Investigators in Olmsted County state an overall age- and sex-adjusted incidence rate 
of HCM of 2.5/100,000 person-years 23. A Japanese study of 12841 worker revealed 
HCM in 22 out of the 1584 (1.38%) individuals who underwent echocardiography 22. The 
prevalence of suspected HCM in 2066 young teenagers screened for the prevention of 
sudden death was 0.2% 27. A retrospective study in western Denmark on a population 2 
798 000 over a 2-year period revealed 20 subjects with HCM with an overall incidence 
3.6/106 population/year 28.  
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1.3 Histopathology 
 
On a macroscopic level HCM is characterised by increased heart weight and 
hypertrophy in any distribution. There is anterior displacement of the papillary muscles 
and mitral valve leaflets 29. HCM is characterised by myocyte hypertrophy and disarray 
(Figure 1). The myocytes display nuclear enlargement, pleomorphism and 
hyperchromasia. Fibrosis, small vessel disease and increased interstitial connective 
tissue are evident as well. The distribution can be regional and patchy 4;29;30. The 
fibrosis leads to expansion of the interstitium and contributes to diastolic dysfunction 
and coats the small coronary vessels 30. In addition reduced coronary flow reserve and 
fibrosis are caused by narrowing of the intramyocardial vessels due to intimal and 
medial smooth muscle hyperplasia 31.  
Figure 1: Histopathology in HCM 
    
Figure reproduced from Hughes (2004). 
29
 The image on the left reveals myocyte disarray in a pinwheel 
pattern. Modified Masson’s shows increased interstitial fibrosis (right image, blue). 
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1.4 Genetics and Pathogenesis 
1.4.1. Sarcomere protein gene mutations 
  
Data on genetics of adults suggest that up to 60% of patients have mutations in 
constituents of the cardiac sarcomere 32. Hundreds of these mutations have been 
identified. Most of the sarcomeric protein mutation are missense 2.  Cardiac myosin-
binding protein C (MYBPC3) and ß myosin heavy chain (MYH7) genes account for 
about 80% of mutations 33. Others include cardiac troponin-T (TNNT2), troponin-I 
(TNNI3), troponin-C, α-tropomyosin (TPM1), cardiac actin (ACTC), titin (TTN) and α -
cardiac myosin heavy chain 2;33-36. By contrast, mutations in proteins of the thin filament, 
account for less than 10% of HCM cases. HCM-causing mutations in TCAP (telethonin), 
MYOZ2 (myozenin-2, also known as calsarcin-1), ANKRD1 (ankyrin repeat and KH 
domain-containing protein 1), PLN (cardiac phospholamban), JPH2 (junctophilin-2), and 
CAV3 (caveolin-3) have also been described; they encode genes responsible for Z-disk 
and non-sarcomeric proteins 37.  
1.4.2. Genotype-Phenotype associations 
 
The establishment of clinically useful relations between genotype and phenotype 
remains elusive in HCM. A recent systematic review reported a higher prevalence of 
family history of HCM and SCD, a younger age at presentation, and greater maximal left 
ventricular in individuals with a sarcomere gene mutation but no difference was reported 
in clinical characteristics when comparing MYBPC3 and MYH7 mutations. However, 
these data were limited by the inconsistency of study design and the small size of many 
study cohorts 38. Some phenotypic associations have been described in the human or 
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murine model. MYH7 mutations are commonly associated with more severe 
hypertrophy, while TNNT2 defects only produce mild hypertrophy but are associated 
with overall higher incidences of sudden cardiac death than other HCM genes 39. MYH7 
mutations tend to present earlier than patients with MYBPC3 mutations, who present 
later in the fifth or sixth decades 40. The pattern of hypertrophy might be linked to 
genetic status. Left ventricular apical hypertrophy has been reported in TNNI3 mutations 
41 and midcavity hypertrophy in ACTC 42 and MYL3 mutations 43. Different mutations in 
the same gene might predispose to certain phenotypes. Some mutations in MYH7 are 
associated with particularly severe hypertrophy and predispose to sudden death 
(Arg403Gln) and heart failure (Arg719Trp). Mutations in Phe513Cys, Leu908Val, and 
Gly256Glu are associated with less severe outcomes 44;45. Homozygous or compound 
heterozygous patients have more severe phenotypes than heterozygous patients 33;46. 
More severe phenotypes can also be associated with an independent second mutation 
in about 5% of patients; triple mutations have been reported in 0.8% 47;48. 
1.4.3. The structure of the sarcomere 
 
Thick myosin filaments, thin actin filaments and titin filaments constitute the cardiac 
contractile machinery of the sarcomere. Accessory proteins such as α-tropomyosin, 
troponin I, troponin T and troponin C regulate the cyclical interaction between the cross-
bridges of the filaments. Individual sarcomeres form myofibrils by connecting in series, 
which are surrounded by a system of membrane-bound tubules called the sarcoplasmic 
reticulum (SR) 49;50.  Z-discs are transverse structures, which delineate the lateral 
borders of sarcomeres and anchor the thin filaments representing the smallest 
functional units in striated muscle. The core of a Z-disc consists of actin filaments 
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coming from adjacent sarcomeres which are crosslinked by α actinin molecules. They 
are the centre of the I-band composed of hundreds of different proteins 51;52. M-bands 
crosslink the thick filaments in the centre. Elastic titin filaments connect both transverse 
structures longitudinally 53.  
1.4.4. The function of the sarcomere 
 
The contractile machinery is activated by Ca2+-controlled conformational change of the 
proteins troponin and tropomyosin and subsequent interaction between troponin-
tropomyosin units along the actin filament. Calcium enters the cell during the cardiac 
action potential through depolarization activated Ca2+ channels. This results in Ca2+ 
release from the sarcoplasmic reticulum (SR). The raised intracellular Ca2+ - 
concentration causes myofilament protein troponin C binding, which results in a 
conformational change and contraction. The tropomyosin strand undergoes azimuthal 
movements on the actin filament and permits cross-bridge cycling.  
A decrease in Ca2+ - concentration, its removal from troponin C and therefore relaxation 
is achieved by several mechanisms that results in transport out of the cell. These 
include reuptake of Ca2+ into the SR through Ca2+ ATP ase, sarcolemmal Na +/ Ca2+ 
exchange, sarcolemmal Ca2+ - ATPase or mitochondrial Ca2+ uniport 50;54;55.  
 
1.4.5. Non-Sarcomeric gene mutations 
 
A further 5-10% of adult HCM are caused by genetic disorders including metabolic and 
neuromuscular diseases, chromosomal abnormalities and genetic syndromes 56. 
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Metabolic disorders include Anderson-Fabry disease 57. A further mutation, which can 
give rise to a phenotype of hypertrophic cardiomyopathy in addition to other 
characteristics such as glycogen vacuoles on cardiac biopsy, Wolff-Parkinson-White 
syndrome and conduction disease is found in the gamma-subunit of AMP kinase 58. 
Other causes include mitochondrial cardiomyopathies 59 and infiltrative diseases such 
as amyloid. 60 
In younger patients hypertrophy of the left ventricle is mostly associated with congenital 
malformations inherited metabolic disorders (glycogen storage diseases), 
neuromuscular diseases and syndromes 61;62. Friedreich’s ataxia is a neuromuscular 
disease with neurological and endocrine sequelae associated with left ventricular 
hypertrophy 63.  Malformation syndrome with autosomal dominant mutations inheritance 
in tyrosine phosphatase, non-receptor-type II protein (PTPNII) include Noonan’s 
syndrome and LEOPARD syndrome 64;65.  
Epigenetic influence and disease modifiers appear to play an important role. They might 
explain variable disease penetrance in terms of outcome, phenotype and age of onset 
66. 
1.4.6. Pathogenesis 
 
Impaired contractile function has been implicated as a compensatory cause of 
hypertrophy leading to diastolic dysfunction 67;68. Conflicting evidence however exists 
with mutations, that increase or decrease contractility 69;70. Impaired biomechanical 
stress sensing leading to hypertrophy in response to load might also be an important 
factor. A protein critical in this regard is titin 71.  
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Abnormal Ca2+ flow and sensitivity has also been implicated in the pathogenesis 72. A 
HCM mutation in α–tropomyosin has been shown to cause hypersensitivity of calcium 
dependent contraction 73. Calcium channel antagonists have also been shown to reduce 
myocardial hypertrophy in transgenic mice with a α-cardiac myosin heavy chain 
mutation 74. A further theory of abnormal bioenergetics has been strengthened by the 
association of cardiac hypertrophy with mitochondrial and AMP kinase mutations 75-77. 
Rats with troponin T mutations revealed a 30% reduction of phosphocreatine : ATP ratio 
by NMR spectroscopy reflecting abnormal cardiac energetics. Similar results are 
evident in patients with sarcomeric mutations even in absence of a phenotype 78;79. 
Fibrosis following apoptosis of myocytes secondary to microvascular ischaemia and 
hypertrophy leads to focal scarring 80;81. This can lead to the arrhythmic phenotype in 
HCM in addition to myocyte disarray and increased muscle mass 82;83. Interestingly no 
association between fibrosis arrhythmia and disarray was found in murine models 84;85.  
1.5 Clinical features 
1.5.1. Diastolic dysfunction 
 
Diastolic dysfunction is a major cause of morbidity in HCM and predisposes to the 
development of atrial fibrillation 86. It is caused by a decrease and prolongation in 
isovolumetric left ventricular relaxation and alteration of the filling dynamics 87-89. 
Abnormalities of the dissociation of actin and myosin in the early filling phase and 
abnormal relaxation leading to impaired filling and abnormal compliance and stiffness of 
the left ventricle are responsible for the increase in left atrial and left ventricular end-
diastolic pressures 89-94. The volume of the left atrium is reflective of the diastolic state of 
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the left ventricle and an important predictor for the development of AF and 
thromboembolism 16. A comprehensive evaluation of diastolic function requires 
transmitral Doppler, tissue Doppler of the mitral annulus, isovolumetric relaxation time 
pulmonary vein flow and pulmonary artery pressure 95;96. These may be abnormal on 
echocardiography prior to development of the phenotype especially in younger 
individuals 97-99. 
A large proportion of symptoms, such as shortness of breath and chest discomfort, are 
secondary to diastolic dysfunction, especially if LVOT obstruction is absent. Restrictive 
cardiomyopathy is a phenotype, in which the diastolic abnormalities dominate the 
clinical picture 2;100. 
Patients with these symptoms commonly respond to therapy with ß-blockers, Ca2+ 
channel antagonist, which prolong diastole and relaxation in addition to diuretics 
(especially spironolactone) and nitrates 2;101;102. Metabolic modulators such as 
perhexiline have been shown to improve diastolic dysfunction and exercise capacity 103.  
In a study of 100 patients with HCM 28% showed a progression of left ventricular 
diastolic dysfunction defined as restrictive filling pattern over a follow up period of 109+-
67 months. Diastolic dysfunction was associated with a poor prognosis in terms of death 
and heart transplantation 104, which represent a therapeutic option in end-stage patients 
105. 
1.5.2. Systolic dysfunction 
 
Systolic impairment is a common feature of HCM. It is also well recognised that a 
proportion of patients with HCM progress to a ‘burnout’ or end-stage phase. In a study 
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of 1080 patients 2.4% of patients presented with systolic impairment. A further 4.8% of 
the patients undergoing echocardiography developed systolic impairment during a 
follow up of 66 months. Systolic impairment is a marker of poor prognosis with almost 
60% of the patients dying or requiring heart transplantation compared with less than 
10% with normal systolic function 106. A study from the US assessed 293 patients over a 
median follow up of 6 years. Seventeen percent of patient developed progressive heart 
failure. Thirty percent of those patients developed end-stage systolic dysfunction and 
48% heart failure, which was classified as non-obstructive with preserved systolic 
function 107.  
Age, family history of HCM and wall thickness are risk factors in the evolution of dilated-
hypokinetic HCM 108. Small vessel disease, ischaemia and progressive fibrosis appear 
to be important in the development of systolic impairment 4;109. Severe microvascular 
dysfunction was reported to be a predictor of adverse LV remodelling and systolic 
dysfunction in a small cohort of patients with HCM assessed by resting and 
dipyridamole myocardial blood flow 110. Elevated levels of serum C-terminal propeptide 
of type I procollagen indicated increased myocardial collagen synthesis and therefore 
fibrosis in sarcomere-mutation carriers without overt disease. This preceded the 
development of left ventricular hypertrophy or fibrosis visible on MRI 111.  
Mechanism such as necrosis, apoptosis, increased fibroblast proliferation, oxidative 
stress and cytokines important in the development of heart failure in ischaemic heart 
disease most likely play a role as well 112;113. Genetic factors also predispose to systolic 
impairment. Certain sarcomeric mutations in α –tropomyosin, troponin T and ß -myosin 
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heavy chain have been implicated in hypertrophic cardiomyopathy and dilated 
cardiomyopathy 114-116.   
Ejection fraction (EF) measurement to assess systolic impairment is challenging and is 
commonly increased when measured in HCM patients in view of increase in wall 
thickness and decreased chamber size 117. Simpson’s method assumes that LV volume 
can be calculated by the summation of a stack of elliptical discs, which are affected by 
hypertrophy. The area is determined by the LV diameter in 2- and 4-chamber views 118.  
CMR has advantages in assessment of systolic function in HCM 119. Doppler and 
systolic strain can determine systolic abnormalities in patients with HCM despite a 
normal ejection fraction 120;121. 
In patients with normal EF but symptoms of breathlessness rate limiting medication to 
improve LV filling and loop diuretics are recommended 3. Patients with systolic 
impairment and heart failure symptoms should be treated according to the ESC 
Guidelines for the management of chronic heart failure. Treatment includes diuretics, ß-
blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor 
blockers (ARB) and mineralocorticoid receptor antagonists (MRA) 122. If drug therapy 
fails CRT can be considered in a subset of patients 3. Cardiac transplantation 
represents a therapeutic option in end-stage patients 105. 
1.5.3. Left ventricular outflow tract obstruction 
 
Approximately a quarter of patients with HCM present with resting left ventricular 
outflow tract obstruction (LVOTO). The gradient is usually measured by continuous 
wave Doppler and associated with posteriorly directed mitral regurgitation due to 
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incomplete leaflet apposition 2. LVOTO is characteristically labile and dynamic. The 
severity of the gradient varies spontaneously and may just be evident post-prandially or 
after haemodynamic challenge 5;123.  
The mechanism described involves the anterior mitral valve leaflet, less commonly the 
posterior leaflet, to undergo Venturi and or drag forces during systole leading to contact 
of the leaflet with the interventricular septum. A high velocity flow in the outflow tract lifts 
the mitral valve towards the septum called the Venturi mechanism. The drag 
mechanism describes the pushing force of flow initiating the anterior motion of the mitral 
valve 124-130. Occasionally this can cause thickening and distortion of the mitral valve 131. 
Obstruction can also be secondary to abnormal insertion of the papillary muscle to the 
mitral valve leaflet 132;133. Right ventricular obstruction is rare but can be observed in 
patients with Noonan’s syndrome 2.  
LVOTO has been shown to be a risk factor for HCM related death, specifically stroke 
and heart failure and a predictor of AF symptomatic progression to NYHA class III and 
IV 134.  A low sudden death rate has been reported in asymptomatic patients with 
LVOTO 135. About two-thirds of patients with symptomatic non-obstructive HCM have 
been shown to have latent LVOTO. Exercise stress echocardiography is therefore 
required in this cohort 136.  
The consequences of LVOTO are at least partially related to LV wall stress and 
myocardial ischaemia with subsequent apoptosis of myocytes and fibrotic replacement 
137;138. Intervention is therefore justified in patients with significant LVOTO and 
significant symptoms on maximal medical therapy 101;139;140. 
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Medical therapy consists of treatment with ß-blockade, Ca2+ channel antagonist and 
addition of disopyramide if symptoms are not adequately controlled 141-144. 
For the minority of patients that require further therapy the gold standard intervention for 
relief of LVOTO remains a septal myectomy operation. Muscle from the subaortic region 
is resected to enlarge the LVOT. This abolishes or decreases SAM and subsequently 
the obstructive gradient 5. In the Morrow procedure a complete median sternotomy is 
performed and the hypertrophied interventricular myocardium is accessed via an 
aoortotomy. Myotomies are performed to excise the myocardial tissue 17;145.  
An alternative to the surgical approach is a percutaneous transluminal septal myocardial 
ablation also termed alcohol septal ablation (ASA) 146. Alcohol is injected in the first 
septal branch through the central lumen of an over-the-wire balloon catheter inflated in 
the target vessel. The optimal septal branch is identified via contrast echocardiography 
147.  About 90% of patients have an acute reduction of their LVOT gradient following the 
procedure 148-151. As part of the remodelling process a further reduction of the gradient 
can be expected within 12 months. During this time patients show significant 
improvement in NYHA class, exercise capacity and peak oxygen consumption 152;153. 
Evidence also exists for reduction in systemic pulmonary artery pressure, left atrial 
dimensions, improvement in left ventricular diastolic dysfunction and improved 
myocardial blood flow 151;154;155. Following ASA a right bundle branch patterns is 
common, whereas left bundle branch block is seen in patients following myectomy 
152;156. 
A meta-analysis of 12 studies to compare outcomes of both procedures does not report 
any significant difference between short and long-term mortality, functional status post-
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procedure, ventricular arrhythmias, the need for re-intervention and mitral regurgitation. 
Importantly a significant increase in RBBB and need for permanent pacing was found in 
the alcohol septal ablation group along with a higher residual gradient in the left 
ventricular outflow tract 157.  
In patients who are not suitable for surgery or ASA, without significant hypertrophy or 
sigmoid shape of the interventricular septum and in elderly patients it has been 
recognised that right ventricular pacing with short AV-delay can reduce the LVOT 
gradient and improved symptoms have been reported 3;158;159. A comparison of DDD 
pacing with myectomy showed a greater reduction in the LVOT and symptomatic 
improvement in patients undergoing surgery 160. Recent data have re-examined the 
efficacy of dual chamber pacing for refractory symptomatic LVOTO 161;162. In a recent 
Cochrane review it was noted that all data derive from small studies and that the few 
randomised trials concentrate on physiological outcome measures rather than hard 
clinical end-points 163;164.  
1.5.4. Arrhythmia 
1.5.4.1. Ventricular arrhythmias 
 
Ventricular arrhythmias are common in patients with HCM. Non-sustained ventricular 
tachycardia (NSVT) occurs in about a quarter of patients. It is typically comparatively 
slow and asymptomatic. This is defined as ≥3 consecutive ventricular beats at ≥120 
beats/min lasting <30 seconds. NSVT is an independent predictor of SCD 135;165-167, 
which is not influenced by frequency, duration or rate 165;168 . The prevalence increases 
with age and is linked to left ventricular wall thickness and also the presence of late 
gadolinium enhancement on cardiac magnetic resonance imaging 165;169.  
34 
 
Asymptomatic NSVT does not usually require antiarrhythmic therapy but if it is poorly 
tolerated ICD therapy and treatment with ß-blockers or amiodarone should be 
considered 17. If a focal origin is suspected an EP study and ablation may be of value 
170. Exercise induced VT carries a high risk of SCD 171. Documented sustained 
monomorphic VT, defined if lasting longer than 30 seconds is uncommon but may be 
associated with LV apical aneurysms 172;173. A study of 178 patients with HCM revealed 
31% of patients with evidence of NSVT on Holter monitoring. This was associated with 
degree of LVH and severity of symptoms and was associated with sudden death 174. 
1.5.4.2. Atrial fibrillation 
 
Atrial fibrillation is the most common arrhythmia in HCM. An Italian registry reports AF in 
18% of 1677 patients over a follow up period of 9.7 years 175. Another study on 900 
patients reveals a prevalence of 21.3% 176. A similar proportion is reported in a cohort of 
480 patients 177. Several predictors have been identified for AF. These include age 178, 
LA dimension 179, NYHA class 177, LVOT gradient and p-wave duration 134, LV wall 
thickness 180 and LV dimensions  and fractional shortening 181. Genotype has also been 
implicated in the development of AF 180;182;183. 
Onset of AF can cause symptomatic deterioration and heart failure. One mechanism for 
this is the loss of the atrial component of cardiac filling 184. AF is also a significant 
predictor of heart-failure related mortality, stroke and severe functional disability. A 
mortality of 15.4% of HCM related causes in patients with HCM compared with a 35% 
mortality of HCM related causes in patients with AF in 480 patients has been reported. 
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The annual HCM mortality was 3% in patients with AF as compared to 1% in patients in 
sinus rhythm 177.  
Treatment consists of ß-blockade and non-dihydropyridine Ca2+ channel antagonism for 
rate- and amiodarone for rhythm control 177;179;184;185. A small study has shown efficacy 
of sotalol in suppression of supraventricular arrhythmias 186. Data on ablation therapy in 
these patients reveals beneficial outcomes with persistence of sinus rhythm in about 
60% of patients at 1 year follow up 187. Due to the high risk of thromboembolism current 
guidelines recommend that all patients with HCM and AF should be anticoagulated 3;17. 
One study on 900 patients reports a cumulative incidence of thromboembolism among 
non-anticoagulated patients twice that of patients on anticoagulation 176. Interestingly 
LVOT obstruction has been shown to be associated with enhanced thrombin generation 
and platelet activity in patients with HCM in sinus rhythm indicating a general 
procoagulant state of HCM patients 188.  
1.5.4.3. Brady-arrhythmia 
 
Sinus node and atrio-ventricular node dysfunction are uncommon in HCM. Treatment is 
according to recent guidelines for cardiac pacing 189. A study investigating 451 patients 
with HCM for severe conduction disease reports sinus node disease or atrioventricular 
conduction abnormalities in 10.6% of patients. Eight percent of patients underwent 
implantation of a pacemaker for primary brady-arrhythmia 190. An EP study on 13 
patients with HCM showed a large incidence of conduction system abnormalities. Ten 
out of 12 patients had a prolonged HV interval 191. A further study on 155 HCM patients 
who underwent an EP study reports a high incidence of sinus node (66%) and His-
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Purkinje HV node disturbances 192. Bradycardia is exacerbated by Ca2+-channel and ß-
blockade used for the treatment of systolic or diastolic dysfunction or LVOT obstruction 
17. In young patients with AV-block specific subtypes of mutations should be suspected 
such as mutations in the gamma-subunit of AMP kinase (PRKAG2) 2;58;193 or desmin 194. 
Cardiac amyloid or Fabry disease might be the cause of conduction disease in older 
individuals 2;60;195;196. It is also a recognised feature in mitochondrial disease 197. 
1.5.5. Thromboembolism 
 
Cerebrovascular accidents, transient ischaemic attacks and peripheral emboli are 
common in HCM and associated with a high burden of morbidity and mortality 176. In a 
cohort of 900 patients 51 (6%) experienced stroke or other vascular events. Forty-one 
of these patients died or were permanently disabled. An incidence of 0.8%/year was 
reported 176. The prevalence of stroke in patients with HCM and AF was 21% in a cohort 
of 480 patients. Several predictors have been identified for thromboembolism. These 
include atrial fibrillation, age and NYHA class III and IV 176, gender, LA dimension, left 
ventricular end diastolic volume and fractional shortening 181. Stroke was less common 
in anticoagulated patients as compared to antiplatelet therapy in two observational 
studies 176;177. The role of anticoagulation with novel agents has not been evaluated. 
1.5.6. Infective endocarditis 
 
Infective endocarditis is a rare complication of HCM with an incidence in patients with 
LVOTO of 3.8 per 1000 person-years and the probability of endocarditis 4.3% at 10 
years. It is usually seen in patients with LV outflow tract obstruction and LA dilatation. 
198. At the moment antibiotic prophylaxis is not generally recommended by the National 
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Institute of Clinical Excellence (NICE Guideline, CG64, March 2008). It should be 
considered for high-risk procedures in patients with prosthetic heart valves or prosthetic 
material used for valve repair, congenital heart disease or a history of previous 
endocarditis in accordance with the ESC/EACTS guidelines on the management of 
valvular heart disease 199.  
1.6. Mortality  
Most current series report an overall cardiovascular mortality of 1-2%/year. Sudden 
cardiac death (SCD), heart failure and thromboembolism are the main causes 200-202. 
One study of 956 patients reports an annual rate of SCD of 1.02%, of heart failure of 
0.55% and of and stroke 0.07% 200. Earlier studies suggested higher rate of mortality 
between 3-6% 203;204. The difference is most likely because of tertiary centre bias as 
patient with high risk patient are more likely to be referred to tertiary institutions 205. 
Earlier recognition of disease due to systematic screening and improved treatment 
undoubtedly play a role as well 200.  
1.6.1. Sudden cardiac death 
 
There are several mechanism thought to responsible for SCD. Abnormal myocardial 
architecture, myocyte disarray and fibrosis lead to increased dispersion and abnormal 
intraventricular conduction. This creates the conditions for re-entry and 
arrhythmogenesis 100;206;207. On a cellular level marked disorganisation of intercalated 
discs with localised abnormalities in desmosome organisation and abnormal gap 
junctions 208 in addition to altered myofilament Ca2+ sensitization have been found to be 
responsible for ventricular arrhythmia 209.  
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Certain subgroups of patients are at higher risk of SCD 210 and require consideration of 
implantation of a defibrillator (ICD) 17. The main course of SCD is episodes of VF or 
sustained VT 211. Conduction disease such as atrioventricular block, asystole and 
pulseless electrical activity can also occur 212-217. A study of 16 patients, who had 
survived a cardiac arrest shows that these patients remain at risk for recurrence of their 
event 213. Non-sustained ventricular tachycardia, maximal wall thickness ≥30mm, family 
history of SCD, unexplained syncope, and abnormal blood pressure response to 
exercise are historically used to estimate the relative risk and to guide implantation of an 
ICD 17.  Patients with multiple risk factors have an increased risk of sudden death 218. 
One clinical approach was that the presence of two risk factors leads to consideration of 
ICD therapy 17. This approach does not take the effect size of individual risk factors into 
consideration and the risk factors are considered as binary 219. Some risk factors such 
as thickness of LV wall have also been reported to carry a continuous risk 220.  
A recent multi-centre longitudinal cohort study of 3675 patients with HCM developed 
and validated a model to predict SCD 221, which is now incorporated into recent ESC 
guidelines 3. The model utilises left atrial diameter, peak left ventricular outflow tract 
gradient and patient age in addition to the risk factors from previous guidelines to 
estimate and individualised absolute risk of SCD at 5 years. Abnormal blood pressure 
response is not included.  
A large majority of data on sudden death stems from patient follow up following 
implantation of ICDs. An Australian study reports an appropriate intervention rate of the 
device of 11%/year 222. A similar ICD intervention rate for secondary prevention 
occurred in 103 out of 502 patients. Out of 726 patients with HCM 45 (6.2%) had an 
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ICD. The annual appropriate ICD therapy rate was 11.1% for secondary prevention and 
1.6% for primary prevention 223. 
1.6.2. Heart Failure 
 
Heart failure is the second most common cause of death in HCM and has been 
discussed in sections 1.5.1. and 1.5.2.. In a study of 106 patients with severe LVH over 
a follow-up of 92 +/- 50 months 13 patients had sudden cardiac deaths, 2 heart failure 
deaths and one patient underwent cardiac transplantation. Five-year survival from heart 
failure death or transplantation was 97.7% 224. A further study of 293 consecutive HCM 
reports development of heart failure in 50 (17%) patients over a median follow-up of 6 
years. Eighteen patients of these died or underwent transplantation 107.  
1.6.3. Stroke related death 
 
Cardiac thrombi causing cerebrovascular accidents, transient ischaemic attacks and 
peripheral embolism are common in HCM leading to a high burden of morbidity and 
mortality 16. This is discussed in Section 1.5.5.  
1.7. Rationale of research questions  
AF and TE are very common comorbidities in patients with HCM. Unfortunately most 
data on these stem from observational studies. The large majority of these studies 
investigate small patient numbers and are poor in quality. The rationale of this work is to 
investigate the characteristics and predictors of AF and TE in the largest multicentre 
cohort assessed to date and to develop a risk prediction tool to guide treatment of 
patients. Exploratory analyses will also address the questions of anticoagulation, the 
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use of the CHA2DS2-VASc score and investigate the effect of AF on mortality and 
treatment with anti-arrhythmics. 
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2 THESIS OBJECTIVES 
 
The aim of this thesis is to examine several clinical aspects of AF and TE in HCM using 
a large cohort of patients. The study cohort consisted of all consecutively evaluated 
patients with HCM, followed at seven European centres: (i) The Heart Hospital, London, 
UK, (ii) A Coruna University Hospital, A Coruna, Spain, (iii) Unit of Inherited 
Cardiovascular diseases, 1st Department of Cardiology, University of Athens, Greece, 
(iv) Institute of Cardiology, University of Bologna, Italy, (v) University Hospital Virgen de 
la Arrixaca, Murcia, Spain, (vi) Monaldi Hospital, Second University of Naples, Italy and 
(vii)  Hospital Universitario Puerta del Hierro, Madrid, Spain. 
 
a) Systematic review of atrial fibrillation (AF) and thromboembolism (TE) in 
patients with HCM and meta-analyse prevalence and incidence of AF and TE 
 
Even though AF and TE are very common in HCM very little is known about predictors, 
treatment, morbidity and mortality. Estimates of incidence and prevalence also vary in 
the available literature.  This analysis is presented in Chapter 3: Systematic review of 
atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy and 
meta-analysis of prevalence and incidence, page 44. 
 
b) Assess prevalence, incidence and predictors of AF in a large multicentre 
cohort 
c) Investigate the effect of AF on mortality 
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Most studies investigating predictors of AF are limited by the size of the cohort with 
cohorts of only a few hundred patients. The primary aim of this study was to investigate 
predictors of AF in a large multicentre cohort. Exploratory analyses were performed to 
investigate the effect of AF on mortality. This analysis is presented in Chapter 4: 
Predictors of atrial fibrillation in patients with hypertrophic cardiomyopathy, page 70.  
 
d) Assess clinical predictors of thromboembolism and derive and validate a risk 
model for estimating the risk of thromboembolism in patients with and without 
documented atrial arrhythmia 
e) Assess the performance of the CHA2DS2-VASc score  
 
AF and TE are common complications of the disease and are associated with adverse 
clinical outcomes and reduced survival. However, HCM is a heterogeneous disorder with 
very variable clinical presentation and the absolute risk of TE – and by implication the 
likely benefit from treatment – in individual patients with different clinical characteristics is 
unknown.  
The analysis of a risk model for estimating the risk of thromboembolic events in patients 
with and without documented atrial arrhythmia and an exploratory analysis to determine 
the performance of the CHA2DS2-VASc score is presented in Chapter 5: Prediction of 
thromboembolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA), 
page 87.  
f) Assess the effect of therapy with vitamin K antagonists (VKA) in patients with 
AF and assess the bleeding risk in patients with HCM using the HAS-BLED score 
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g) Investigate effect of antiarrhythmic therapy on the development of AF  
 
Current ESC and ACCF/AHA guidelines recommend anticoagulation in all patients with 
HCM and AF. The efficacy of vitamin K antagonists has not been proven in patients with 
HCM and AF in randomised controlled trials. The exploratory analyses to assess the 
outcome of therapy with vitamin K antagonists (VKA) in patients with AF and their 
bleeding risk and the effect of antiarrhythmic therapy on the prevention of AF are 
presented in Chapter 6: Outcome of anticoagulation and antiarrhythmic therapy in 
patients with HCM, page 110. 
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3 Systematic review of atrial fibrillation and 
thromboembolism in patients with 
hypertrophic cardiomyopathy and meta-
analysis of prevalence and incidence 
 
3.1. Aims 
 
Many cohort studies have shown that atrial fibrillation (AF) is a common complication of 
the disease and that it is associated with adverse clinical outcomes. However, current 
guidelines for the management of AF lack detailed advice on the management of AF in 
patients with HCM because of an absence of adequately powered studies on 
pharmacological treatment strategies in this setting. The primary aim of this study was to 
perform a systematic review and meta-analysis of the published literature on atrial 
fibrillation and thromboembolism in patients with HCM to determine the feasibility of 
developing a disease specific algorithm for the management of AF. 
 
3.2. Methods 
 
The methodology and presentation of the review are based on the recommendations of 
the PRISMA statement 225. 
3.2.1. Study selection 
Two independent reviewers (OG and AA) performed the literature search and checked 
the eligibility of each study. Disagreement between the two reviewing authors was 
resolved by consensus with a third author (PE). 
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PubMed and Web of Science electronic databases were searched using the terms 
“hypertrophic cardiomyopathy”, “atrial fibrillation”, “stroke” and “thromboembolism” in 
title and abstract. Reviews, case reports and abstracts were excluded from the analysis. 
The reference lists of reviews, letters and editorials were scrutinised for additional 
papers. All searches were limited to ‘human’ and ‘English’. The last search was 
performed on 1st September 2012. Studies were eligible if they investigated atrial 
fibrillation and/or stroke or thromboembolism as primary or secondary outcome in a 
prospective or retrospective study. 
The following variables were extracted from each study: number of patients, sex, mean 
age, predictors of AF and thromboembolism, prevalence of AF and thromboembolism, 
definitions of AF and stroke/thromboembolism and length of follow up (tables 1, 2). 
Where available the effect of antiarrhythmics, anticoagulants, and AF ablation on 
morbidity and mortality was investigated. 
 
3.2.2. Meta-analysis 
Studies reporting prevalence data for atrial fibrillation and thromboembolism were 
included in the meta-analysis. Not all studies provided standard error (SE) of the 
prevalence and so SE was calculated using the prevalence data and sample size in 
each study with the following formula: 
SE (prevalence) =  
 
sizesample
prevalenceprevalence )1( 
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Assuming that the estimated values for prevalence follow a normal distribution we 
calculated 95% confidence interval for population prevalence. Incidence rate for each 
study was calculated using number of new cases and median follow-up time provided 
by the study. Standard error of incidence rate was calculated assuming Poisson 
distribution of number of new cases. A random effect meta-regression model 226 was 
then used to combine the prevalence data and to obtain the pooled (overall) prevalence 
and incidence for AF and thromboembolism separately. The overall prevalence was the 
weighted average of the prevalence across different studies, where weights were 
calculated using measures of precision (inverse of the variance of the prevalence). 
Intra- and inter-study variances were used in the calculation of precision. The intra-
study variance was the variance of the prevalence obtained as above (square of SE) for 
each study. The inter-study variance, a parameter of the random effects meta-
regression model, was estimated using method of moments 226. The inter-study 
variance was used to adjust for the heterogeneity in prevalence between studies. 
Heterogeneity between studies was further assessed using I2 statistic, which represents 
the proportion of total variability in the prevalence data attributable to the heterogeneity 
between the studies. The overall estimate, obtained using this method, takes more 
weight from the study with higher precision associated with smaller SE. A random effect 
meta-analysis was conducted to obtain an overall cut-off value of LA diameter for both 
SR and AF, using average median values of LA diameter from individual studies in 
patients with SR and AF. All these computations were conducted using Stata Statistical 
Software, version 11. 
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3.3. Results 
Two hundred and fifty six articles in Pubmed and 79 in Web of Science fulfilled the search 
criteria. After adjustment for duplicates, 262 unique records remained. Following 
exclusions (figure 2), 33 records reporting data on 7381 patients remained (table 1) 134;176-
184;201;202;227-247. All studies were observational or used retrospective data collection.  
 
Figure 2: Study selection process. The flow chart shows the study selection process 
        
                                         
 From Guttmann et al (2013) 16 
3.3.1. Incidence and prevalence of thromboembolism and AF 
 
The definitions of AF varied between studies, but most included patients with paroxysmal 
and chronic AF. Six studies investigated only paroxysmal AF. Four studies defined 
paroxysmal AF by duration or symptoms (table 1).  
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The pooled overall prevalence of paroxysmal and permanent AF was 22.45 % (95% CI: 
20.13-24.77, I2= 78.9%, p<0.001), figure 3. The pooled overall prevalence of all 
thromboembolic complications in patients with HCM and AF was 27.09% (95% CI: 20.94-
33.25, I2= 61.4%, p<0.01), figure 4. The pooled overall incidence of paroxysmal and 
permanent AF was 3.08 % (95% CI: 2.63-3.54, I2= 86.5%, p<0.001), figure 5. The reported 
overall incidence of AF in two studies was 2 and 2.6%, respectively 177;232. The pooled 
overall incidence of all thromboembolic complications in patients with HCM and AF was 
3.75% (95% CI: 2.88-4.61, I2=37.9% (p=0.1), figure 6.  
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Figure 3: Prevalence of AF 
The forest plot from random effect meta-analysis showed study specific prevalence and the pooled 
(overall) prevalence of AF. The heterogeneity between the study was assessed by  statistic estimated 
as, I
2
=78.9%, p<0.001.The overall prevalence is 22.45%. 
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Figure 4: Prevalence of thromboembolism 
The forest plot from random effect meta-analysis showed study specific prevalence and the pooled 
(overall) prevalence of thromboembolism in patients with HCM and AF. The heterogeneity between the 
study was assessed by  statistic estimated asI
2
=61.4%, p<0.01.The overall prevalence is 27.09%. 
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Figure 5: Incidence of AF 
The forest plot from random effect meta-analysis showed study specific incidence and the pooled 
(overall) incidence of AF. The heterogeneity between the study was assessed by  statistic estimated 
asI
2
=86.5% p<0.01.The overall incidence rate is 3.08 per 100 patients per year. 
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Figure 6: Incidence of thromboembolism 
The forest plot from random effect meta-analysis showed study specific incidence and the pooled 
(overall) incidence of thromboembolism in patients with HCM and AF. The heterogeneity between the 
study was assessed by  statistic estimated as I
2
=37.9%, p=0.1.The overall incidence rate is 3.75 per 
100 patients per year. 
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3.3.2. Predictors of AF and thromboembolism 
 
The lack of patient level data and heterogeneity between studies means that it is not 
possible to model clinical predictors of AF and thromboembolism. LA size and volume 
were associated with the development of AF in 15 studies and for the development of 
thromboembolism in 3 studies. Age was reported as a predictor of AF in 7 studies and of 
2I
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thromboembolism in 2 studies. Other variables reported to be associated with an 
increased risk of AF and thromboembolism are shown in tables 1 and 2. 
 
Table 1: Prevalence and predictors of AF in HCM 
Study PN Male MA DT AF AF 
Cases 
Prev
AF 
(%) 
Definition of 
AF 
Follow 
up 
Robinson K 
et al, JACC 
1990 184 
174 NS 47 NS 52 30 pAF or 
established AF 
0.5-24 
years 
Spirito P et 
al, Am J 
Cardiol 
1992 178 
127 NS 55 age, lower 
degree of 
LVH, LV 
cavity size 
NS NS AF for>6 
months 
2 years 
Cecchi F et 
al, JACC 
1995 179 
202 NS 41+-17 LA size, age 57 28 NS NS 
Shigematsu 
Y et al, 
JpnCirc J 
1995 228 
92 77 54 LA size, LV 
effective 
chamber 
size 
24 26 NS 6.5 
years 
Higashikaw
a M et al, 
JpnCirc 
1997 233 
83 60 55.5+-
7.8 
age 19 22.8 NS 2889 +- 
1675 
days 
Cecchi F et 
al, Heart 
1997 229 
110 83 46+-15 p wave 
duration 
41 37.3 AF on Holter 
monitor 
clinically 
evident 
episodes, 
excluded 
chronic AF at 
enrolment 
12 
years 
Gruver EJ 
et al, Am J 
Cardiol 
1999 183 
24 NS NS Arg663His 
beta-
cardiac 
myosin 
heavy 
chain 
mutation 
NS NS NS NS 
Maron B et 
al, JAMA 
1999 201 
277 152 47 NS 50 18 NS 8.1 
years 
Maron B et 744 462 45+-20 NS 153 21 pAF and 8+-7 
54 
 
al, Circ 
2000 202 
chronic AF years 
Olivotto I 
et al, Circ  
2001 177 
480 292 45+-20 LA 
dimension,  
NYHA class 
III-IV, age 
107 22 pAF or chronic 
AF, inclusion 
of AF at 
enrolment and 
follow up 
9.1 +- 
6.4 
years 
Doi Y, J 
Cardio 
2001 231 
91 62 51+-14 age, LA 
dimensions  
22 24 pAF or chronic 
AF 
6.7 +- 
4.8 
years 
Yamaji K et 
al, 
Cardiovasc 
Pathol 
2001 234 
10 8 60+-22 LV fibrosis NS NS NS 7 years 
Maron B et 
al, JACC 
2002 176 
900 551 46+-20 NS 192 21.3 NS 7 +- 7 
years 
Ogimoto A 
et al, J 
Human 
Gen 2002 
182 
138 104 63+-31 LA 
dimension, 
ANP, ACE II 
genotype 
26 19 NS 10.5 +- 
7 years 
Kose S et 
al, Clin 
Cardiol 
2003 236 
48 30 43 +-
11 
LA 
diameter, p 
wave 
dispersion 
NS NS pAF if>10mins NS 
Tani T, J 
Am Soc 
Echocardio
gr 2004 230 
141 96 61+-13 LA volume  31 22 pAF if 
symptomatic 
only, chronic 
AF excluded 
NS 
Ozdemir O 
et al, Int J 
Card 2004 
134 
80 45 53.1±1
1.1 
p wave 
duration, 
LA 
diameter, 
LVOT 
gradient 
27 34 AF duration > 
30s 
NS 
Ho H et al,  
Am J Med 
2004 227 
118 62 54+-18 NS 41 35 NS 5.8+-
4.3 
Losi MA et 
al, Am J 
Cardio 
2004 232 
150 91 41+-17 age, LA 
diameter, 
LA volume 
index, FS of 
LA 
20 13.3 NS 5.2 +- 
2.9 
years 
Cecchi F et 
al, Am 
1677 1033 44+-19 NS 302 18 pAF or chronic 
AF, 263/1491 
9.7+-
7.7 
55 
 
Heart J 
2005 245 
(18%) of AF 
during follow 
up 
years 
Lee et al, 
Cardiol 
2006 241 
40 30 56.1+-
10.8 
LA size 3 7.5 prevalence of 
pAF during 
follow up 
72.2+-
60.1 
months 
Lee et al, 
Clin Cardiol 
2007 246 
163 84 NS NS 20  12.2 pAF during 
follow up, 
20.3% of 
patients had 
AF during 
initial 
evaluation 
5.3+-
4.1 
years 
Kitoaka H 
et al, Circ J 
2006 243 
137 95 52 +-
13 
NS 29 25 22 patients in 
AF at initial 
evaluation, 29 
patients 
developed 
during follow 
up, prevalence 
of AF 
(pAF/persisten
t AF) 
developed 
during follow 
up 
11.4 +- 
5.7 
years 
Nagai T et 
al, Circ J 
2007 180 
110 86 53+-13 EDN2 A 985 
allele, LA 
dimension, 
IV wall 
thickness, 
LV mass 
index 
26 24 Prior pAF or 
persistent AF 
excluded 
13+-7 
years 
Bunch T et 
al, Am J 
Cardiol 
2007 237 
86 57 56.6+-
16.1 
ST changes 
and PVC on 
ECG 
12 14 NS 2.6+-
2.8 
years 
Kubo T et 
al, Circ J 
2009 181 
261 173 64+-14 Age, NYHA 
III-IV, 
LVEDD, FS, 
LA 
dimension 
74 28 pAF and 
persistent AF 
4 years 
retrosp
ective 
Yang WI et 
al, J Am Soc 
Echocard 
2009 235 
81 51 57 ± 
14 
NS NS NS NS 41 ± 17 
months 
Papavassili 87 54 58+-13 LA size, LGE 37 43 AF duration of NS 
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u et al, J 
Cardiovasc 
Magn 
Reson 2009 
239 
1 hour  
Pedrosa et 
al, Chest 
2010 242 
80 39 47 LA 
diameter, 
severity of 
OSA 
13 16.2
5 
NS NS 
Shigematsu 
Y et al, J 
Cardiol 
2011 244 
88 71 65+-11 LA size, 
impaired 
LV function 
NS NS NS NS 
Tani T et al, 
Cardiovasc
ular 
Ultrasound 
2011 240 
102 73 61+-13 NS 23 23 pAF if 
symptomatic 
only, chronic 
AF excluded 
30.8+-
10 
months 
Moon J et 
al, Am J 
Cardiol. 
2011 238 
454 316 61+-11 NS 72 16 NS 43+-20 
months 
Maron B et 
al, AM J 
Cardiol 
2012 247 
26 8 92.2+-
2 
NS 9  34.6 NS 9.4+-7 
years 
From Guttmann et al (2013) 16 
ACE: angiotensin converting enzyme 
ANP: atrial natriuretic peptide 
DT: determinant 
FS: fractional shortening 
IV: interventricular wall 
LA: left atrium 
LGE: late gadolinium enhancement 
LV: left ventricle 
LVEDD: left ventricular end diastolic diameter 
LVH: left ventricular hypertrophy 
LVOT: left ventricular outflow tract 
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MA: mean age 
NYHA: New York Heart Association Class 
NS: not specified 
OSA: obstructive sleep apnoea 
pAF: paroxysmal atrial fibrillation 
PN: patient number 
PVC: premature ventricular contractions 
Table 2: prevalence and predictors of thromboembolism in HCM 
Study PN Male MA DT CT PT 
(%) 
Definition of stroke Follow 
up 
Robinson 
K et al, 
JACC 
1990 184 
174 NS 47 NS 12 23 prevalence of systemic 
thromboembolism in HCM+AF 
population, including those at 
onset of AF and during long 
term follow up 
0.5-24 
years 
Shigemat
su Y et al, 
Jpn Circ J 
1995 228 
92 77 54 NS 11 46 incidence and prevalence of 
systemic thromboembolism in 
HCM+AF population 
6.5 
years 
Higashika
wa M et 
al, Jpn 
Circ 1997 
233 
83 60 55.5
+-7.8 
AF, Age 10 52.6 prevalence of ischaemic stroke 2889 +- 
1675 
days 
Maron B 
et al, 
JAMA 
1999 201 
277 152 47 NS 11 4 stroke in total  population 8.1 
years 
Maron B 
et al, Circ 
2000 202 
744 462 45+-
20 
NS NS NS 11 stroke related deaths 8+-7 
years 
Olivotto I 
et al, Circ  
2001 177 
480 292 45+-
20 
NS 23 21 prevalence of stroke in HCM 
AF patients 
9.1 +- 
6.4 
years 
Doi Y, J 
Cardio 
2001 231 
91 62 51+-
14 
NS 5 22.7 prevalence of total embolic 
events in total HCM cohort 
10.9%, prevalence of non-fatal 
stroke in HCM+AF group is 
22.7% 
6.7 +- 
4.8 
years 
Maron B 900 551 46+- NYHA 44 21.3 5.6% prevalence of systemic 7 +- 7 
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et al, 
JACC 
2002 176 
20 III-V, AF,  
age 
thromboembolism in total 
HCM population, 16.1% of 
strokes in HCM+AF, 21.3% of 
systemic thromboembolism in 
HCM+AF 
years 
Ogimoto 
A et al, J 
Human 
Gen 2002 
182 
138 104 63+-
13 
NS 15 58 thromboembolic events in the 
HCM+AF group 
10.5 +- 
7 years 
Tani T, J 
Am Soc 
Echocardi
ogr 2004 
230 
141 96 61+-
13 
NS 6 19.4 prevalence of stroke in the 
HCM+pAF group 
NS 
Ho H et 
al,  Am J 
Med 
2004 227 
118 62 54+-
18 
NS 10 24.4 nonfatal  stroke and fatal 
stroke associated with 
HCM+AF, 10/41 
5.8+-
4.3 
years 
Cecchi F 
et al, Am 
Heart J 
2005 245 
167
7 
1033 44+-
10 
NS 76 5.10 stroke or peripheral 
embolisation in HCM group, 
76/1491 during follow up 
9.7+-
7.7 
years 
Lee et al, 
Cardiol 
2006 241 
40 30 56.1
+-
10.8 
NS 4 10 total population 72.2+-
60.1 
months 
Kitaoka H 
et al, Circ 
J 2006 243 
137 95 52 +-
13 
NS NS NS  6 deaths of stroke related to 
AF 
11.4 +- 
5.7 
years 
Bunch T 
et al, Am 
J Cardiol 
2007 237 
86 57 56.6
+-
16.1 
NS 3 3.5 prevalence of stroke in total 
population 
2.6+-
2.8 
years 
Kubo T et 
al, Circ J 
2009 181 
261 173 64+-
14 
AF, 
gender, 
LVEDD, 
FS, LA 
15 20 prevalence of embolic 
complications in the HCM+AF 
patients 
4 years 
retrosp
ective 
Yang WI 
et al, J 
Am Soc 
Echocard 
2009 235 
81 51 57 ± 
14 
LA 
volume 
index 
5 6 total stroke patient population 41 ± 17 
months 
Tani T et 
al, 
Cardiovas
cular 
Ultrasoun
102 73 61+-
13 
LAV 18 18 prevalence of stroke in total 
population 
30.8+-
10 
months 
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d 2011 240 
Moon J 
et al, Am 
J Cardiol. 
2011 238 
454 316 61+-
11 
NS 26 6 prevalence of stroke in total 
population 
43+-20 
months 
Maron B 
et al, AM 
J Cardiol 
2012 247 
26 8 92.2
+-2 
NS 2 22% prevalence of non-fatal stroke 
in HCM+AF 
9.4+-7 
years 
From Guttmann et al (2013) 16 
AF: atrial fibrillation 
CT: Cases of thromboembolism 
DT: determinants of thromboembolism 
FS: fractional shortening 
HCM: hypertrophic cardiomyopathy 
LAV: left atrial volume 
LVEDD: left ventricular end diastolic diameter 
MA: mean age 
NYHA: New York Heart Association Class 
pAF: paroxysmal atrial fibrillation 
PN: patient number 
Prev AF: prevalence of AF 
PT: prevalence of thromboembolism 
 
The pooled overall LA diameter in patients with SR was 38.03 mm (95% CI: 34.62-41.44), 
figure 7. The heterogeneity between the studies was estimated as (p=0.95). 
The pooled overall LA diameter in patients with AF or paroxysmal AF was 45.37 mm (95% 
CI: 41.64-49.04), figure 8. The I2 statistic was estimated as  (p=0.96). One 
study reported an LA diameter of more than 40mm to be predictive of AF (p<0.01)179 
%02.02 I
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and another an LA diameter of more than 42mm predictive of AF with a sensitivity of 
96% and a specificity of 81% 134. 
 
Figure 7: Left atrial diameter in patients with SR 
The forest plot from random effect meta-analysis showed study specific LA diameter for patients in SR 
and the pooled (overall) LA diameter. The heterogeneity between the study was assessed by  statistic 
estimated as  , p=0.95. The overall cut-off point or diameter value is 38.03 in patients with 
SR. 
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Figure 8: LA diameter in AF 
The forest plot from random effect meta-analysis showed study specific LA diameter for patients in AF or 
paroxysmal AF and the pooled (overall) LA diameter. The heterogeneity between the study was assessed 
by  statistic estimated as  , p=0.96.The overall cut-off point or diameter value is 45.37 in 
patients with AF. 
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3.3.3. Mortality 
A meta-analysis of mortality in the AF population was not possible due to limited data. 
Studies reporting statistically significant higher mortality in patients with AF compared to 
patients in sinus rhythm are presented in table 3. 
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Table 3: mortality data in available studies in whole population and in AF patients 
Study Patient 
Number 
Male mean 
age 
Follow 
up 
Mortality mortality AF patients 
Robinson 
K et al, 
JACC 1990 
184 
174 NS 47 0.5-24 
years 
NS 36.5% disease related 
death, 11.5% SD, 14% 
5-year mortality, 29% 
10-year mortality, 35% 
15-year mortality  
Cecchi F et 
al, JACC 
1995 179 
202 NS 41+-17  6% cardiovascular 
death related to 
HCM, 0.6%  annual 
mortality for 
cardiovascular 
disease, 0.1% SD  
impaired survival 
p<0.005, cumulative 
mortality rate after 15 
years 24% (AF) vs 3% 
(SR) 
Higashika
wa M et 
al, Jpn Circ 
1997 233 
83 60 55.5+-
7.8 
2889 
+- 
1675 
days 
7.2 % CD CD 5.3%  (AF) vs 7.8% 
(SR) 
Maron B 
et al, 
JAMA 
1999 201 
277 152 47 8.1 
years 
10.5% HRD, 1.3% 
annual HCM 
mortality, 0.7% SD , 
6.5% 5 year mortality, 
10.5% 10 year 
mortality, 16.8% 15 
year mortality 
NS 
Maron B 
et al, Circ 
2000 202 
744 462  8+-7 
years 
12% HRD, 6% sudden 
and unexpected, 1.4% 
annual mortality for 
HCM related death 
1.4% , 0.7% SD  
NS 
Olivotto I 
et al, Circ  
2001 177 
480 292 45+-20 9.1 +- 
6.4 
years 
15.4% HCM related 
causes 
35% HCM related 
causes, annual HCM 
mortality 3% in AF vs 
1% SR 
Doi Y, J 
Cardio 
91 62 51+-14 6.7 +- 
4.8 
11% CD, 6%  SD 32% cardiovascular 
death in AF group, 
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2001,J 
Cardiol 231 
years 13.6% SD, 3% 5- year 
mortality rate  SR vs 
34% AF (cardiovascular 
death) 
Ho H et al,  
Am J Med 
2004 227 
118 62 54+-18 5.8+-
4.3 
years 
1.6% annual 
cardiovascular 
mortality 
NS 
Cecchi F et 
al, Am 
Heart J 
2005 245 
1677 1033 44+-19 9.7+-
7.7 
1.3% annual all cause, 
1% cardiovascular 
mortality, 0.4% SD 
NS 
Lee et al, 
Cardiol 
2006 241 
40 30 56.1+-
10.8 
72.2+-
60.1 
month
s 
no mortality in apical 
HCM 
NS 
Lee et al, 
Clin 
Cardiol 
2007 246 
163 84  5.3+-
4.1 
years 
2.8% annual  all-cause 
mortality rate, 0.8% 
annual cardiovascular 
mortality rate, 0.2% 
SD  
NS 
Modified from Guttmann et al (2013) 16 
AF:  atrial fibrillation 
SR: sinus rhythm 
HRD: HCM related death 
CD: cardiac death 
SD: sudden death 
NS: not specified 
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3.3.3.4. Treatment of AF 
 
We identified no randomised trials of antiarrhythmic drugs, oral anticoagulants or 
radiofrequency ablation. The results from observational studies on drug treatment and AF 
ablation are reported in tables 4 and 5. 
Table 4: AF ablation in patients with HCM 
Study PN Male mean 
age 
AF RP 
(%) 
SR follow 
up 
predictor 
of poor 
outcome 
Di Donna P et 
al, Europace 
2010 248 
61 44 54+-13 pAF, recent & 
longstanding 
persAF 
52 67% at of 
follow up 
29+-16 
month
s 
LAV, NYHA 
Bunch T et al, 
J Cardiovasc 
Electrophysio
l 2008 249 
33 25 51+-11 pAF, persAF, 
permAF 
 62% at 1 
year  
1.5+-
1.2 
years 
persAF/cA
F, LAV, 
advance 
diastolic 
disease 
Gaita F et al, 
Am J Cardiol 
2007 187 
26 18 58+-11 pAF, permAF 19.
20 
64% at of 
follow up 
19+-10 
month
s 
permAF 
Kilicaslan F et 
al, Heart 
Rhythm 2006 
250 
27 NS 55+- 10 pAF, persAF, 
permAF 
26 52% at of 
follow up 
341 +- 
237 
days 
NS 
From Guttmann et al (2013) 16 
cAF  chronic AF 
LAV: left atrial volume 
NYHA: New York Heart Association class 
NS: not specified 
pAF: paroxysmal atrial fibrillation 
persAF: persistent AF 
permAF :permanent atrial fibrillation 
PN: patient number 
RP: redo procedures 
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Table 5: Studies of amiodarone treatment and anticoagulation in HCM patients 
 
Study Therapy PN Study design Outcome 
Robinson K et 
al, JACC 1990 184 
A 174 45 of 52 patients with AF 
received conventional therapy  
alone (25) or followed by 
amiodarone,  7 amiodarone 
only 
fewer alterations in drug 
therapy, fewer embolic 
episodes and more remained 
in SR, fewer DCCV attempts 
Cecchi F et al, 
JACC 1995 179 
A 202 63 patients to manage NSVT, 
cardioversion or control or 
prevent AF or recurrence of 
cardiac arrest 
No sudden death 
Olivotto I et al, 
Circ  2001 177 
A 480 55.8% of patients with pAF  no difference of duration of 
SR and survival 
Doi Y, J Cardio 
2001 231 
W 91 45% of patients with AF 
anticoagulated 
42% of patients without 
warfarin vs 10% with warfarin 
experienced 
thromboembolism 
Maron B et al, 
JACC 2002 176 
W 900 43.2%  patients with AF 
anticoagulated 
cumulative incidence of 
thromboembolism among 
non-anticoagulated patients 
was twice that of patients 
anticoagulated (31% vs 18%) 
Olivotto I et al, 
Circ  2001 177 
W 480 55.1% patients with AF 
anticoagulated 
stroke less common 10% vs 
non treated 39% p<0.05 
Higashikawa M 
et al, Jpn Circ 
1997 233 
W 83 37% (7 out of 19) of HCM 
patients with AF treated with 
warfarin  
Ischaemic strokes in 6 out of 
7 warfarin treated HCM 
patients with AF, INR<2 in 5 
cases 
From Guttmann et al (2013) 16 
A: amiodarone 
AF: atrial fibrillation 
NSVT: non sustained ventricular tachycardia 
pAF: paroxysmal atrial fibrillation 
PN: patient number 
SR: sinus rhythm 
W: warfarin 
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3.4. Discussion 
This review shows that studies on atrial fibrillation in HCM are very heterogeneous with 
respect to patient characteristics, follow up duration, inclusion criteria and endpoint 
definition. All are retrospective and observational in design and there are no randomised 
control trials of any treatment strategy. The data do show that AF occurs in about a fifth 
of patients with HCM, and strongly suggest that it is associated with adverse outcomes. 
3.4.1. Data quality 
Major limitations of existing data are the difference in age and sex distribution in the 
study populations and the small size (typically less than 150 patients) of most cohorts. 
There is also substantial variation in inclusion criteria and in the definition of AF. For 
example, some studies included patients who were in AF at the time of diagnosis 181;184 
whereas others excluded patients who were in AF at enrolment and reported only on those 
individuals that developed AF during the follow up period.229;232;241;246 Similarly, some 
reports included only patients with paroxysmal AF, but the definition of paroxysmal AF was 
highly variable in that some included AF only when associated with symptoms,230;240 or 
when the AF was of a prespecified duration.134;178;236;239 Finally, groups of investigators 
have published their cohorts in more than one study. It is impossible to discern the overlap 
in patient populations.176;177;201;202;230;240;241;246 but the duplicate studies report different 
follow up duration and total population size. We therefore conclude that the overall 
estimate obtained by meta-analysis was not significantly affected 235;238;241. 
3.4.2. Prevalence and incidence of thromboembolism 
All studies showed that AF in patients with HCM is associated with thromboembolism. The 
prevalence figures were influenced by duration of follow up (the two studies reporting the 
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highest prevalence of thromboembolic events had significantly longer duration of follow up 
compared to the other studies 182;233) and by the definition of thromboembolism. For 
example, some studies consider all thromboembolic events including cerebral and 
peripheral emboli in the reported prevalence of thromboembolic events 182;184;228 whereas 
others only report the prevalence of stroke 177;233. 
 
3.4.3. Predictors of AF 
The pathophysiological conditions that predispose to atrial arrhythmia in patients with 
HCM are poorly understood, but diastolic dysfunction and mitral regurgitation (usually in 
the context of outflow obstruction) are a major cause of increased atrial size and stretch. 
Small cross-sectional studies show associations with myocardial fibrosis detected by 
gadolinium enhanced cardiac magnetic resonance imaging and reduced hyperaemic 
myocardial blood flow determined using PET, but these phenomena are probable 
surrogates for disease severity rather than specific mechanisms or triggers for AF.239;251 
Several workers have postulated that patients with HCM have a primary atrial as well as 
a ventricular myopathy, but supportive evidence for this is scant. While heterogeneity 
between studies meant that it was not possible to perform a meta-analysis of all 
suggested predictors for AF and thromboembolism, the majority of reports examining 
this question found that LA size, LA volume, and age were independently associated 
with AF, suggesting that these should be considered when evaluating individual patients 
risk of developing AF.  
There are no prospective randomised trials of any therapy for AF in HCM and, as this 
review shows, only limited observational data on pharmacological and non-
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pharmacological treatment strategies.177;179;184 Evidence that amiodarone therapy 
maintains sinus rhythm and reduces embolic episodes comes from a single study.184 
Data on warfarin use are similarly limited, but there are observational data reporting a 
lower incidence of stroke in patients treated with warfarin compared to those on 
antiplatelet therapy or no treatment.176;177;231 
 
To date only small non-randomised studies have examined the efficacy of AF ablation in 
HCM, but the data accrued so far suggest that repeat procedures are frequently 
required and long term maintenance of sinus rhythm is achieved in no more than 50-
60% of patients.187;248-250 
3.5. Limitations 
 
The review examines only those studies that investigated atrial fibrillation and/or stroke 
or thromboembolism as primary or secondary outcome, but we acknowledge that data 
on prevalence of AF are included in other observational cohort studies reporting on 
other aspects of the disease. 
3.6. Conclusions 
This review shows that the published literature is insufficient to create a robust clinical 
tool for the prediction of AF or thromboembolic risk. Nevertheless, most data suggest 
that once patients have AF, they have a high risk of thromboembolism and should be 
anticoagulated. More challenging is the management of patients with LA enlargement 
but no evidence for atrial arrhythmia. Given that LA diameter and volume are 
consistently shown to be independently associated with AF, patients with atrial 
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enlargement should as a minimum be monitored on a regular basis in order to detect 
AF. The role of prophylactic anticoagulation in this group should be evaluated in 
randomised prospective trials. 
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4 Predictors of atrial fibrillation in 
hypertrophic cardiomyopathy (HCM Risk-
AF) 
4.1. Aims 
 
Most studies investigating predictors of AF are limited by the size of the cohort with 
cohorts of only a few hundred patients 177-179;184;201;233;244. The primary aim of this study 
was to investigate predictors of AF in a large multicentre cohort. Exploratory analyses 
were performed to investigate the effect of AF on mortality.  
4.2. Methods 
4.2.1. Study design and overview 
 
This study uses data from a retrospective, multicentre longitudinal cohort–the 
Hypertrophic Cardiomyopathy Outcome Investigators (www.HCMRisk.org) 167. 
The study conforms to the principles of the Helsinki declaration. The sponsors of this 
study did not have a role in study design, data collection, analysis, and interpretation. 
O.G., M.P., R.O., and P.E. had access to all data and final responsibility to submit the 
article. The authors from each participating centre guarantee the integrity of data from 
their institution. All investigators have agreed to the article as written. 
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4.2.2. Study population and participating centres  
 
The study cohort consisted of all consecutively evaluated patients with HCM, followed at 
seven participating European centres: (i) The Heart Hospital, London, UK, (ii) A Coruna 
University Hospital, A Coruna, Spain, (iii) Unit of Inherited Cardiovascular diseases, 1st 
Department of Cardiology, University of Athens, Greece, (iv) Institute of Cardiology, 
University of Bologna, Italy, (v) University Hospital Virgen de la Arrixaca, Murcia, Spain, 
(vi) Monaldi Hospital, Second University of Naples, Italy and (vii)  Hospital Universitario 
Puerta del Hierro, Madrid, Spain.  Some patients from this cohort are reported in other 
recently published studies 167;190;219;252-260. 
Only adult patients (≥16 years of age) were studied. HCM was defined as a maximum 
left ventricular wall thickness ≥15 mm unexplained solely by loading conditions 261 or in 
accordance with published criteria for the diagnosis of disease in relatives of patients 
with unequivocal disease 20. Patients with known inherited metabolic diseases or 
syndromic causes of HCM were excluded from the study. For the development of the 
predictors of AF, patients with AF at first evaluation were excluded from the analysis. 
4.2.3. Patient assessment and data collection  
 
All patients underwent clinical assessment, pedigree analysis, physical examination, 
resting and ambulatory electrocardiography and transthoracic echocardiography. Each 
participating centre collected data independently. Patients were reviewed every 6–12 
months or earlier if there was a change in symptoms.  
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4.2.4. Clinical outcomes  
 
The primary outcome was paroxysmal, permanent or persistent AF detected on ECG, 
Holter monitoring or device interrogation. The secondary outcome was all-cause and 
cardiovascular mortality (defined as sudden cardiac death, heart failure related death, 
stroke related death and other cardiac death). 
4.2.5. Selection of predictors and coding  
 
Following a review of the literature completed in September 2012 , predictors of AF that 
have been reported previously in patients with HCM were considered as candidate 
predictor variables 16. Clinical parameters were used as pre-specified predictor variables 
only when associated with AF in at least one published study. All parameters were 
uniformly defined in all participating centres. In addition to these variables, predictors 
known to be associated with AF in the general population such as hypertension, 
diabetes mellitus and vascular disease were considered (table 6). All predictors are at 
baseline evaluation. 
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Table 6: Definition of pre-specified predictor variables assessed at baseline evaluation 
Predictor 
variable 
Definition Coding 
Sex Male or female 181 Binary, 
male/female 
Age Age at first evaluation in participating centres 176;233 Continuous, 
years 
AF Physician reported detection of paroxysmal, permanent of persistent 
AF on ECG or Holter monitoring 176;233 
Binary, yes/no 
NYHA NYHA class at first evaluation 176 Categorical, 1,2 
and 3-4 
LA Anterior-posterior left atrial diameter determined by 2D 
echocardiography in the parasternal long axis or short-axis plane at 
time of first evaluation 181 
Continuous, mm 
MWT The greatest LV wall thickness measured at the level of the mitral 
valve, papillary muscles, and apex in the parasternal short-axis plane 
using 2-D echocardiography at time of evaluation 210 
Continuous, mm 
FS LV end-diastolic dimension-LV end-systolic dimension)/ LV end-
diastolic dimension measured by M-Mode or 2D echocardiography at 
time of evaluation 181  
Continuous, % 
LVOT 
max 
The maximum LV outflow gradient determined at rest and with 
Valsalva provocation (irrespective of concurrent medical treatment) 
using pulsed and continuous wave Doppler from the apical three- and 
five-chamber views. Peak outflow tract gradients were determined 
using the modified Bernoulli equation: Gradient = 4V2, where V is the 
peak aortic outflow velocity 171 
Continuous, 
mmHg 
Hyperten
sion  
Diagnosis of hypertension prior to first evaluation, as per CHA2DS2-
VASc score 262;263 
Binary, yes/no 
Diabetes  Diagnosis of diabetes prior to first evaluation, as per CHA2DS2-VASc 
score 262;263 
Binary, yes/no 
Vascular 
disease  
Myocardial infarction, complex aortic plaque and peripheral arterial 
disease, as per CHA2DS2-VASc score 
262;263 
Binary, yes/no 
  
AF: atrial fibrillation, NYHA: New York Heart Association Functional classification, LA: Left atrial size, MWT: Maximal wall 
thickness, FS: Fractional shortening, LVOT max: maximum LV outflow gradient 
4.2.6. Sample size 
 
A minimum of 10 AF events were required per coefficient estimated to ensure that the 
regression coefficients were estimated with adequate precision. The 740 AF endpoints 
observed in this cohort over a 10 year follow-up period allow the estimation of all 
regression coefficients (as shown in table 6) in a multivariable regression model and 
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variable selection from a set of relevant predictors of AF also adjusting for possible 
centre effects.  
4.2.7. General statistical methods 
 
STATA (version 12) and R (version 3.0) were used for the statistical analyses. For 
descriptive results, variables are expressed as mean ± standard deviation (SD), median 
and interquartile range (IQR) or counts and percentages as appropriate. The follow-up 
time for each patient was calculated from the date of their first evaluation at participating 
centres to the date of the relevant endpoint or to the date of their most recent 
evaluation. The annual event rate was calculated by dividing the number of patients 
reaching the endpoint by the total follow-up period for that endpoint. The Kaplan–Meier 
method was used to estimate the cumulative probability for the occurrence of an 
outcome.  
4.2.8. Missing data 
 
The characteristics of patients with missing information were compared to those of 
patients with complete information to investigate bias due to missing data. Logistic 
regression was used to identify the predictors of missingness. Data were assumed to be 
missing at random and values for the missing predictors were imputed using multiple 
imputation techniques based on chained equations 264. The multiple imputation model 
included all predictors of missingness, the outcome, all pre-specified predictors of the 
risk model, and the estimate of the cumulative hazard function 265. Rubin’s rules were 
used to combine the estimates from 30 imputed data sets 266.  
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4.2.9. Univariate and multivariate analysis 
 
Univariable and multivariable Cox regression models were fitted and tested for non-
linearity of continuous predictors by inclusion of quadratic terms. The final fully adjusted 
Cox regression model for AF was developed using backwards elimination with a 15% 
significance level was used to select the final predictors 34. The proportional hazards 
assumption was investigated using Schoenfeld residuals 35. The entire cohort was used, 
making efficient use of the data 36. A sensitivity analysis for centre effects was 
performed by including centre in the model. 
4.2.10. Comparison of mortality in patients with AF and SR 
 
Cardiovascular and non-cardiovascular mortality was compared in patients with AF and 
SR at first evaluation over a follow up period of ten years. Patients with AF at first 
evaluation were included for this analysis.  
4.2.11. Relation of LA size to AF  
 
A sub-analysis was performed to assess the relationship between risk of AF and LA 
size.  
4.3. Results 
4.3.1. Baseline clinical characteristics  
 
The study cohort comprised 5104 patients; 197 patients, who were only seen once at 
baseline evaluation and an additional 659 patients with AF prior to first evaluation were 
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excluded for the analysis of AF events. The study cohort for the AF analysis consisted 
of 4248 patients. The baseline clinical characteristics are shown in table 7.  
Table 7: Clinical characteristics of whole cohort and in patients with and without AF 
  
whole cohort 
  
no AF 
  
AF 
 variable total mean/n SD/% total  mean/n SD/% total  mean/n SD/% 
Age 4244 47.73 16.3 3505 46.73 16.52 739 52.48 14.34 
LA 4075 43.1 7.2 3355 42.12 6.8 720 47.69 7.26 
MWT 4200 19.47 5.23 3461 19.33 5.27 739 20.14 5.02 
FS 3862 0.41 0.09 3174 0.41 0.09 688 0.41 0.1 
LVOT max 3634 32.67 41.49 2975 31.11 40.4 659 39.75 45.43 
AF 4248 740 0.17 
      Female 4247 1504 0.35 3507 1214 0.35 740 290 0.39 
NYHA II 4069 1365 0.34 3356 1057 0.31 713 308 0.43 
NYHA III,IV 4069 377 0.09 3356 269 0.08 713 108 0.15 
Hypertension 4149 1171 0.28 3432 914 0.27 717 257 0.36 
Diabetes 3500 225 0.06 2863 168 0.06 637 57 0.09 
FH SCD 4117 995 0.24 3397 810 0.24 720 185 0.26 
Vascular 
disease 
3068 66 0.02 2431 41 0.02 637 25 0.04 
 
SD: Standard deviation, n: Number, LA: Left atrial size, MWT: Maximal wall thickness, FS: Fractional shortening, LVOT max: 
maximum LV outflow gradient, AF: atrial fibrillation, NYHA: New York Heart Association Functional classification, FH SCD: Family 
history of sudden cardiac death 
4.3.2. AF events during follow-up 
 
During a follow up period of 22,743.04 patient years (median 5.4 years), 740 (17.4%) 
patients reached the primary endpoint within 10 years from first evaluation (57.8% 
paroxysmal and 42.2% permanent and persistent). The 5 and 10 year cumulative 
incidence rates of AF were 16.0% (95% CI 14.6%-17.5%) and 33.3% (95% CI 30.7%-
36.1%), respectively. The clinical characteristics of patients with and without AF are 
shown in table 7.  
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4.3.3. Missing data 
 
Missing data per variable are presented in table 8.  
 
Table 8: Missing data per variable 
 
Variable n Total % 
Sex 1 4,248 0.02 
Age 4 4,248 0.09 
NYHA 179 4,248 4.21 
MWT 48 4,248 1.13 
LA 173 4,248 4.07 
LVEDD 194 4,248 4.57 
LVESD 376 4,248 8.85 
LVOT max 614 4,248 14.45 
Hypertension 99 4,248 2.33 
Diabetes 748 4,248 17.61 
Vascular disease 1,180 4,248 27.78 
 
n: Number, AF: atrial fibrillation, NYHA: New York Heart Association Functional classification, MWT: Maximal wall thickness, LA: 
Left atrial size, LVEDD: Left ventricular end-diastolic dimension, LVESD: left ventricular end-systolic dimension,  LVOT max: 
maximum LV outflow gradient 
 
4.3.4. Univariable and multivariable analyses 
 
The models were developed based on the 740 events within the first 10 years of follow-
up. Univariable analyses are shown in table 9. Only maximal LV wall thickness was 
found to have a nonlinear association with AF and so a quadratic term was included as 
a candidate predictor in the multivariable analysis. 
Multivariable Cox regression revealed an association between AF and the following: 
female sex, LA diameter, NYHA class II, NYHA class III/IV, hypertension and vascular 
disease. There was a significant centre effect as part of a sensitivity analysis (shown in 
78 
 
table 9 and 10). The clinical characteristics according to centre are displayed in table 
11. 
 
Table 9:  Univariable and multivariable analysis for predictors of AF in HCM  
 
Univariable 
analysis 
   
Multivariable 
analysis 
   Predictor HR p CI Predictor HR P CI 
Female 1.27 <0.001 1.10 - 1.47 Female 1.34 <0.001 1.14 - 1.56 
Age10 1.35 <0.001 1.29 - 1.41 Age10 1.23 <0.001 1.17 - 1.30 
NYHA II 1.75 <0.001 1.49 - 2.05 NYHA II 1.29 <0.001 1.10 - 1.52 
NYHA III,IV 2.96 <0.001 2.37 - 3.69 NYHA III,IV 1.66 <0.001 1.32 - 2.08 
LA5 1.6 <0.001 1.53 - 1.68 LA5 1.1 <0.001 1.09 - 1.11 
MWT 1.02 <0.001 1.01 - 1.03 Hypertension 1.17 0.06 0.99 - 1.38 
FS 0.87 0.75 0.38 - 2.01 Vascular disease 1.4 0.1 0.94 - 2.09 
LVOT max 1.01 <0.001 1.00 - 1.01 
    LVEDD 1.02 <0.001 1.01 - 1.03 
    LVESD 1.01 0.02 1.00 - 1.03 
    Hypertension 1.72 <0.001 1.48 - 2.01 
    Diabetes 1.52 <0.001 1.16 - 1.99 
    Vascular disease 2.4 <0.001 1.61 - 3.58 
    MWT1 1.21 <0.001 1.11 - 1.31 
    MWT2 1 <0.001 0.99 - 1.00 
     
Age10: Hazard ratio for 10 year increments, NYHA: New York Heart Association Functional classification, LA5: Hazard ratio for 
left atrial size for 5mm increments, MWT: Maximal wall thickness, FS: Fractional shortening, LVOT max: maximum LV outflow 
gradient, LVEDD: Left ventricular end-diastolic dimension, LVESD: left ventricular end-systolic dimension, HR: Hazard ratio, p: p-
value, CI: 95% confidence interval 
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Table 10:  Multivariable analysis of AF predictors and sensitivity analysis for centre 
effect 
 
variable HR P CI 
Female 1.34 <0.001 1.14 - 1.56 
Age10 1.23 <0.001 1.17 - 1.30 
NYHA II 1.29 <0.001 1.10 - 1.52 
NYHA III,IV 1.66 <0.001 1.32 - 2.08 
LA5 1.10 <0.001 1.09 - 1.11 
Hypertension 1.17 0.06 0.99 - 1.38 
Vascular disease 1.40 0.10 0.94 - 2.09 
Athens 1.27 0.03 1.03 - 1.56 
Bologna 0.69 0.01 0.52 - 0.92 
Coruna 0.72 0.01 0.57 - 0.92 
Madrid 1.65 0.01 1.16 - 2.34 
Murcia 0.65 <0.001 0.48 - 0.87 
Naples 0.44 0.01 0.25 - 0.81 
 
Age10: Hazard ratio for 10 year increments, NYHA: New York Heart Association Functional classification, LA5: Hazard ratio for 
left atrial size for 5mm increments, HR: Hazard ratio, p: p-value, CI: 95% confidence interval. 
 
Table 11:  Clinical characteristics according to centre 
 
Centre variable total mean/n (SD)/% min max 
LONDON Age 1928 44.75 15.45 16.03 88.37 
  LA 1872 43.06 7.48 19.00 75.00 
  MWT 1925 19.43 5.54 7.00 43.00 
  FS 1842 0.42 0.09 0.10 0.82 
  LVOT max 1612 27.01 38.04 1.00 260.00 
  AF 1928 378 0.20     
  Female 1928 696 0.36     
  NYHA II 1816 702 0.39     
  NYHA III/IV 1816 156 0.09     
  Hypertension 1831 369 0.20     
  Diabetes 1218 56 0.05     
  FH SCD 1810 516 0.29     
  Vascular disease 1219 12 0.01     
ATHENS Age 493 45.01 16.12 16.00 82.44 
  LA 493 42.96 6.01 23.00 65.00 
  MWT 493 18.06 4.03 12.00 37.00 
  FS 493 0.40 0.07 0.07 0.64 
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  LVOT max 493 31.95 36.14 2.00 175.00 
  AF 493 117 0.24     
  Female 492 141 0.29     
  NYHA II 493 158 0.32     
  NYHA III/IV 493 37 0.08     
  Hypertension 493 126 0.26     
  Diabetes 493 31 0.06     
  FH SCD 493 157 0.32     
  Vascular disease 493 7 0.01     
BOLOGNA Age 439 49.52 15.69 17.16 90.26 
  LA 433 44.19 7.62 20.00 75.00 
  MWT 439 20.20 4.89 15.00 39.00 
  FS 425 0.42 0.11 0.06 0.77 
  LVOT max 439 35.07 49.04 4.00 237.00 
  AF 439 55 0.13     
  Female 439 152 0.35     
  NYHA II 439 132 0.30     
  NYHA III/IV 439 37 0.08     
  Hypertension 439 123 0.28     
  Diabetes 439 23 0.05     
  FH SCD 439 69 0.16     
  Vascular disease 439 7 0.02     
CORUNA Age 500 54.87 15.58 16.72 89.09 
  LA 469 43.30 6.99 23.00 73.00 
  MWT 468 20.18 5.10 12.00 42.00 
  FS 456 0.42 0.09 0.14 0.70 
  LVOT max 220 60.97 53.03 3.00 299.00 
  AF 501 87 0.17     
  Female 501 175 0.35     
  NYHA II 487 164 0.34     
  NYHA III/IV 487 46 0.09     
  Hypertension 501 210 0.42     
  Diabetes 463 57 0.12     
  FH SCD 496 94 0.19     
  Vascular disease 501 5 0.01     
MADRID Age 188 53.40 16.94 16.99 85.61 
  LA 181 42.46 7.06 26.00 62.00 
  MWT 186 20.76 5.43 7.00 41.00 
  FS 173 0.42 0.12 0.08 0.74 
  LVOT max 183 33.39 42.87 1.00 250.00 
  AF 188 37 0.20     
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  Female 188 70 0.37     
  NYHA II 186 38 0.20     
  NYHA III/IV 186 10 0.05     
  Hypertension 188 82 0.44     
  Diabetes 188 23 0.12     
  FH SCD 186 32 0.17     
  Vascular disease 187 16 0.09     
MURCIA Age 529 51.91 17.13 16.47 88.68 
  LA 510 42.23 6.99 23.00 70.00 
  MWT 521 18.96 5.13 8.00 43.00 
  FS 460 0.39 0.10 0.05 0.72 
  LVOT max 529 36.88 41.94 1.00 150.00 
  AF 529 54 0.10     
  Female 529 201 0.38     
  NYHA II 524 141 0.27     
  NYHA III/IV 524 85 0.16     
  Hypertension 527 216 0.41     
  Diabetes 529 25 0.05     
  FH SCD 527 77 0.15     
  Vascular disease 59 8 0.14     
NAPLES Age 167 44.58 15.03 16.31 77.24 
  LA 117 44.38 7.11 25.00 66.00 
  MWT 168 20.38 5.02 11.00 40.00 
  FS 13 0.38 0.17 0.16 0.78 
  LVOT max 158 31.72 26.05 7.00 135.00 
  AF 170 12 0.07     
  Female 170 69 0.41     
  NYHA II 124 30 0.24     
  NYHA III/IV 124 6 0.05     
  Hypertension 170 45 0.26     
  Diabetes 170 10 0.06     
  FH SCD 166 50 0.30     
  Vascular disease 170 11 0.06     
 
SD: Standard deviation, n: Number, LA: Left atrial size, MWT: Maximal wall thickness, FS: Fractional shortening, LVOT max: 
maximum LV outflow gradient, AF: atrial fibrillation, NYHA: New York Heart Association Functional classification, FH SCD: Family 
history of sudden cardiac death 
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4.3.5. Comparison of mortality in patients with AF and SR 
 
There were 4835 patients with follow up clinical data and recorded information on cause 
of death. Patients with unknown date (47 patients) or cause of death (25 patients) were 
excluded from this analysis. The prevalence of cardiovascular death was 8.38%; CI= 
[7.6%-9.2%]   (405 out of 4835 patients) with an incidence of 6.66%; 95%; CI= [5.9 %-
7.3%] (317 out of 4835 patients) at 10 year follow-up. The prevalence of non-
cardiovascular death was 4.84%; 95%; CI= [4.2%-5.4%] (234 out of 4835 patients) with 
an incidence of 3.91%; 95%; CI= [3.4%-4.5%] (189 out of 4835 patients) at 10 year 
follow-up. The incidence of cardiovascular death was 4.92% in the SR group and 
10.86% in the AF group (difference in proportions = 5.9%; 95% CI= [4.1%-7.8%]). The 
incidence of non-cardiovascular death was 3.15% in the SR group and 5.92% in the AF 
group (difference in proportions= 2.8%; 95% CI= [0.1%- 4.2%]). The Kaplan-Meier 
curves for cardiovascular and non-cardiovascular death in patients with AF and SR are 
displayed in Figure 9a. There is an increased mortality in patients with 
permanent/persistent AF compared with paroxysmal AF (difference in proportions = 
8.1%; 95% CI= [4.5%-11.7%] (Figure 9b). 
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Figure 9: Kaplan-Meier failure estimates comparing cardiovascular (left) and non-
cardiovascular mortality (right) in patients with AF and SR at baseline 
evaluation 
 
  
Breakdown of cardiovascular death: 
SR group: sudden death: 96, heart failure related: 38, stroke related: 9, other cardiac: 29 
AF group: sudden death: 38, heart failure related: 59, stroke related: 17, other cardiac: 31 
 
Figure 9b: Kaplan-Meier failure estimates comparing mortality (cardiovascular and 
non-cardiovascular) in patients with permanent/persistent AF compared 
with paroxysmal AF  
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4.3.6. Relation of LA size to AF  
 
Figure 10 reveals the relationship between LA size and 5 year risk of AF. There was a 
linear relationship between LA size and AF risk above a diameter of 40 mm.   
 
Figure 10: Relationship of LA size with risk of AF 
  
 
 
4.4. Discussion 
 
This study confirms the high prevalence and incidence of AF in this patient group and 
the association between atrial size, NYHA class and age 16;177;270 For the first time in a 
HCM population, we demonstrate an association with several other patient 
characteristics including sex, hypertension and vascular disease. 
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4.4.1. Prevalence, Incidence of AF and mortality 
  
The prevalence and incidence of AF and mortality are in line with previous cohort 
studies in patients with HCM 16;177;179. Evidence for the detrimental effect of AF on 
survival is limited in HCM 177;231 but in this study we show a significant association with 
cardiovascular mortality. Interestingly the survival curves for patients in SR and AF 
separate about 3 years into the follow up period with a higher proportion of heart failure 
and stroke related death in the AF group. The explanation for this delay is uncertain, but 
for patients who die of heart failure, it is possible that the onset of AF accelerates 
disease progression. Alternatively, AF may simply be a marker that identifies patients 
with advanced disease who are already on an accelerated trajectory to ventricular 
failure. There was also a trend towards increased mortality evident for non-
cardiovascular mortality in the AF group. This is likely to represent a complex interplay 
between some miscoding of deaths, age at AF onset and the adverse consequences of 
cardiac disease and therapy on general health. 
4.4.2. Significant centre effect in sensitivity analysis 
 
The significant centre effect as part of a sensitivity analysis can be explained by the 
difference in some of the clinical characteristics of the participating cohorts including 
mean age, mean follow-up time and prevalence of atrial fibrillation. Further work is 
necessary to understand this, but it might reflect systematic differences in referral 
patterns. 
 
86 
 
4.4.3. Clinical implications 
 
This study confirms the importance of atrial fibrillation in the natural history of HCM 271.  
The findings in this and our previous study on stroke in HCM 272 suggest that patients 
with risk factors for AF should be undergo frequent ambulatory ECG monitoring to 
detect atrial arrhythmia and be considered for early prophylactic anticoagulation. The 
identification of associations with common cardiovascular risk factors such as vascular 
disease and hypertension is not by itself that surprising, but shows that management of 
these risk factors should be given equal priority to other disease-specific complications.  
4.4.4. Limitations 
 
The patient population in this study is large and diverse but the predictors identified in 
this study may not apply to patients with different characteristics. In particular, the study 
excludes paediatric patients (less than 16) and patients with metabolic or syndromic 
disorders in whom other disease characteristics may be influence the risk of AF 
development. 
4.5. Conclusions 
 
Readily available clinical parameters can be used to identify patients at high risk of AF 
who require more frequent monitoring and early anticoagulation. In the exploratory 
analysis AF was associated with increased cardiovascular and non-cardiovascular 
mortality. 
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5 Prediction of thromboembolic risk in 
patients with hypertrophic cardiomyopathy 
(HCM Risk-CVA) 
5.1. Aims 
 
AF and TE are common complications of the disease and are associated with adverse 
clinical outcomes and reduced survival 177;179;202;232;245;270. However, HCM is a 
heterogeneous disorder with very variable clinical presentation and the absolute risk of 
TE – and by implication the likely benefit from treatment – in individual patients with 
different clinical characteristics is unknown 3;262;263;273.  
The primary aim of this study was to derive and validate a risk model for estimating the 
risk of TE in patients with HCM. Exploratory analyses were performed to determine 
clinical predictors of TE and the performance of the CHA2DS2-VASc score 
274.  
5.2. Methods 
  
5.2.1. Study design and overview 
Data from a retrospective, multicentre longitudinal cohort – the Hypertrophic 
Cardiomyopathy Outcome Investigators (www.HCMRisk.org) 167 – were used in the 
development of the prognostic model.  
The study conforms to the principles of the Helsinki declaration. The sponsors of this 
study did not have a role in study design, data collection, analysis, and interpretation. 
O.G., M.P., R.O., and P.E. had access to all data and final responsibility to submit the 
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article. The authors from each centre guarantee the integrity of data from their 
institution. All investigators have agreed to the article as written. 
 
5.2.2. Study population and participating centres 
The study cohort has been described in detail in Chapter 4.The study cohort consisted 
of all consecutively evaluated patients with HCM, followed at seven European centres: 
(i) The Heart Hospital, London, UK, (ii) A Coruna University Hospital, A Coruna, Spain, 
(iii) Unit of Inherited Cardiovascular diseases, 1st Department of Cardiology, University 
of Athens, Greece, (iv) Institute of Cardiology, University of Bologna, Italy, (v) University 
Hospital Virgen de la Arrixaca, Murcia, Spain, (vi) Monaldi Hospital, Second University 
of Naples, Italy and (vii)  Hospital Universitario Puerta del Hierro, Madrid, Spain. Some 
patients from this cohort are reported in other recently published studies 167;190;219;252-260.  
Only adult patients (≥16 years of age) were studied. HCM was defined as a maximum 
left ventricular wall thickness ≥15 mm unexplained solely by loading conditions 3 or in 
accordance with published criteria for the diagnosis of disease in relatives of patients 
with unequivocal disease 20. Patients with known inherited metabolic diseases or 
syndromic causes of HCM were excluded from the study. Patients with a history of AF 
that had experienced TE prior to first evaluation at the centre were also excluded from 
the analysis. 
  
5.2.3. Patient assessment and data collection 
Patients were reviewed every 6–12 months or earlier if there was a change in 
symptoms. All patients underwent clinical assessment, pedigree analysis, physical 
examination, resting and ambulatory electrocardiography and transthoracic 
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echocardiography. Each centre collected data independently using the same 
methodology. 
5.2.4. Clinical outcomes 
The primary outcome was a thromboembolic event defined as a composite of 
cerebrovascular accident (CVA), transient ischaemic attack (TIA) or systemic peripheral 
embolus as defined in the CHA2DS2-VASc score. CVA was defined as a focal 
neurologic deficit of sudden onset as diagnosed by a neurologist, lasting more than 24h 
and caused by ischaemia. TIA was defined as a focal neurologic deficit of sudden onset 
as diagnosed by a neurologist, lasting less than 24 h. Peripheral embolism was defined 
as TE outside the brain, heart, eyes, and lungs 274.  
 
5.2.5. Selection of predictors and coding  
Following a review of the literature completed in September 2012 , predictors of TE that 
have been reported previously in patients with HCM were considered as candidate 
predictor variables 16.  Clinical parameters were used as pre-specified predictors only 
when associated with TE in at least one published study and were uniformly defined in 
all centres. In addition, predictors included in the CHA2DS2-VASc score and maximal LV 
wall thickness and peak left ventricular outflow tract (LVOT) gradient were considered 
for the analysis (table 12). Clinically plausible interactions between selected variables 
such as age and AF and age and vascular disease were also assessed. All predictors 
were assessed at baseline evaluation. 
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Table 12: Definition of pre-specified predictor variables assessed at baseline evaluation 
Predictor 
variable 
Definition Coding 
Sex Male or female 181 Binary, 
male/female 
Age Age at first evaluation in participating centres 176;233 Continuous, 
years 
VKA Use of Vitamin K antagonist at first evaluation Binary, yes/no 
AF Physician reported detection of paroxysmal, permanent of persistent 
AF on ECG or Holter monitoring 176;233 
Binary, yes/no 
TE Thromboembolism: CVA, TIA, peripheral embolus, as per CHA2DS2-
VASc score 262;263 
Binary, yes/no 
NYHA NYHA class at first evaluation 176 Categorical, 1,2 
and 3-4 
LA Anterior-posterior left atrial diameter determined by 2D 
echocardiography in the parasternal long axis or short-axis plane at 
time of first evaluation 181 
Continuous, mm 
MWT The greatest LV wall thickness measured at the level of the mitral 
valve, papillary muscles, and apex in the parasternal short-axis plane 
using 2-D echocardiography at time of evaluation 210 
Continuous, mm 
FS LV end-diastolic dimension-LV end-systolic dimension)/ LV end-
diastolic dimension measured by M-Mode or 2D echocardiography at 
time of evaluation 181  
Continuous, % 
LVOT 
max 
The maximum LV outflow gradient determined at rest and with 
Valsalva provocation (irrespective of concurrent medical treatment) 
using pulsed and continuous wave Doppler from the apical three- and 
five-chamber views. Peak outflow tract gradients were determined 
using the modified Bernoulli equation: Gradient = 4V2, where V is the 
peak aortic outflow velocity 171 
Continuous, 
mmHg 
Hyperten
sion  
Diagnosis of hypertension prior to first evaluation, as per CHA2DS2-
VASc score 262;263 
Binary, yes/no 
Diabetes  Diagnosis of diabetes prior to first evaluation, as per CHA2DS2-VASc 
score 262;263 
Binary, yes/no 
Vascular 
disease  
Myocardial infarction, complex aortic plaque and peripheral arterial 
disease, as per CHA2DS2-VASc score 
262;263 
Binary, yes/no 
Heart 
failure 
Heart failure, especially moderate to severe LV systolic dysfunction, 
defined arbitrarily as left ventricular ejection fraction (LVEF) <40% 
(calculated by FS), as per CHA2DS2-VASc score 
262;263 
Binary, yes/no 
 
VKA: Vitamin K antagonist, AF: atrial fibrillation, TE: thromboembolic event, NYHA: New York Heart Association Functional 
classification, LA: Left atrial size, MWT: Maximal wall thickness, FS: Fractional shortening, LVOT max: maximum LV outflow 
gradient 
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5.2.6. Sample size 
A minimum of 10 thromboembolic events were required per coefficient estimated by the 
model to ensure that the regression coefficients of the model were estimated with 
adequate precision 275. The 172 TE endpoints observed in this cohort over a 10 year 
follow-up period allow the estimation of up-to 17 regression coefficients with adequate 
precision and were sufficient for development of the risk model. 
5.2.7. General statistical methods 
STATA (version 12) and R (version 3.0) were used for the statistical analyses. For 
descriptive results, variables are expressed as mean ± standard deviation (SD), median 
and interquartile range (IQR) or counts and percentages as appropriate. The follow-up 
time for each patient was calculated from the date of their first evaluation at participating 
centres to the date of the study endpoint, death, heart transplantation, cerebral 
haemorrhage or to the date of their most recent evaluation. The annual event rate was 
calculated by dividing the number of patients reaching the endpoint by the total follow-
up period for that endpoint. The Kaplan–Meier method was used to estimate the 
cumulative probability for the occurrence of an outcome.  
5.2.8. Missing data 
The characteristics of patients with missing information were compared to those of 
patients with complete information to investigate bias due to missing data. Logistic 
regression was used to identify the predictors of missingness. Data were assumed to be 
missing at random and values for the missing predictors were imputed using multiple 
imputation techniques based on chained equations 264. The multiple imputation model 
included all predictors of missingness, the outcome, all pre-specified predictors of the 
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risk model, and the estimate of the cumulative hazard function 265. Rubin’s rules was 
used to combine the estimates from 30 imputed data sets 266.  
5.2.9. Model development 
All pre-specified predictors were candidates for inclusion in the final risk model. To 
account for potential non-linear relationships we considered the addition of quadratic 
terms for all continuous predictors. Due to sample size issues this was done in a pre-
selection procedure where bi-variable models for each predictor and its quadratic term 
were fitted. Suspected interactions were also examined in a similar manner.   
The model was developed based on the 172 events within the first 10 years of follow 
up. Backward elimination with a 15% significance level was used to select the predictors 
for the final risk model 267. Centre was not included to allow the model to be used in 
patients from other centres. However, a sensitivity analysis for centre effect was 
performed by including centre in the model. The proportional hazards assumption 
required by the Cox model was investigated using Schoenfeld residuals 268. The risk 
model was developed using the entire cohort.  
5.2.10. Model validation 
Bootstrapping was used to evaluate the performance of the model. This is the most 
efficient internal validation procedure as all aspects of the model development, including 
variable selection are validated 269. Two hundred bootstrap samples were generated for 
each imputed dataset and the optimism-adjusted performance measures from the 
imputed datasets were combined using Rubin’s rules 276. The calibration slope was 
used to assess the degree of agreement between the observed and predicted hazards 
of thromboembolism 277. A value close to 1 suggests good overall agreement. Graphical 
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comparisons of the observed and predicted thromboembolism at 5 years were 
performed. The C-index and D-statistic were used to measure how well the model 
discriminated between patients with high and low risk of thromboembolism 167;278-280. A 
value of 0.5 for C-index indicates no discrimination and a value equal to 1 indicates 
perfect discrimination. The D-statistic can be interpreted as the log hazard ratio for 
having thromboembolism between the low and high risk groups of patients. A model 
with no discriminatory ability results in a value of 0 for D-statistic, with increasing values 
indicating greater separation. 
 
5.2.11. Model presentation 
The probability of TE at 5 years for an individual patient was calculated using the 
following equation, derived from the Cox proportional hazards model: 
 
P TE at 5 years = 1 – S0(t)
exp (Prognostic Index) 
 
where S0(t) is the average survival probability at time t (i.e. at 5 years), and the 
prognostic index is the sum of the products of the predictors and their coefficients.  
 
5.2.12. Calculation of CHA2DS2-VASc score 
The CHA2DS2-VASc score was calculated for a subset of patients with AF not treated 
with VKA at baseline 262;263;281. The distribution of the score and number of events 
according to the score was determined. 
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5.2.13. Relation of patient characteristics to thromboembolic risk 
Prespecified sub-analyses were performed to assess the relationship between five year 
risk of TE and age, vascular disease and LA size. Secondary analyses were performed 
in patients in SR who experienced TE and patients with AF who did not experience TE.  
 
5.3. Results 
5.3.1. Baseline clinical characteristics  
During the study period 5104 patients were evaluated, of whom 197 were seen only 
once for baseline evaluation and were excluded from the analysis. Eighty six patients 
with a history of AF and TE prior to first evaluation were excluded. The final study cohort 
consisted of the remaining 4821 patients and the baseline clinical characteristics are 
shown in table 13. Table 14 displays the cohort characteristics according to centre.  
Table 13: Clinical characteristics of whole cohort and in patients with and without 
thromboembolic endpoint (TE) 
  
Whole cohort 
 
No TE 
 
TE  
 predictor total 
mean 
(SD)/n(%) 
total 
mean 
(SD)/n(%) 
total 
mean 
(SD)/n(%) 
Age 4817 48.99 (16.40) 4645 48.74 (16.39) 172 55.73 (15.40) 
LA 4627 43.97 (7.74) 4460 43.82 (7.68) 167 47.83 (8.37) 
MWT 4768 19.44 (5.15) 4599 19.42 (5.18) 169 20.05 (4.16) 
FS 4358 0.41 (0.10) 4198 0.41 (0.10) 160 0.40 (0.09) 
LVOT max 4168 31.95 (40.94) 4023 31.85 (40.96) 145 34.72 (40.46) 
Female 4820 1740 (36.10) 4648 1666 (35.84) 172 74 (43.02) 
Prior TE 4821 80 (1.66) 4649 71 (1.53) 172 9 (5.23) 
AF 4815 600 (12.46) 4643 552 (11.89) 172 48 (27.91) 
VKA 4818 443 (9.20) 4646 410 (8.82) 172 33 (19.19) 
NYHA II 4615 1584 (34.32) 4450 1519 (34.13) 165 65 (39.29) 
NYHA III,IV 4615 494 (10.70) 4450 456 (10.24) 165 38 (23.03) 
Vascular 3588 89 (2.48) 3438 79 (22.98) 150 10 (6.67) 
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disease 
Hypertension 4712 1414 (30.00) 4541 1354 (29.82) 171 60 (35.09) 
Diabetes 4020 293 (7.29) 3868 279 (7.21) 152 14 (9.21) 
 
SD: Standard deviation, n: Number,  LA: Left atrial size, MWT: Maximal wall thickness, FS: Fractional shortening, LVOT max: 
maximum LV outflow gradient, TE: thromboembolic event, AF: atrial fibrillation, VKA: Vitamin K antagonist, NYHA: New York 
Heart Association Functional classification 
Breakdown of AF in whole cohort: paroxysmal 314, persistent 102, permanent 181, not specified 3 
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Table 14: Cohort characteristics according to centre 
Centre Variable total mean(SD)/n Min max 
LONDON Age 2082 45.28 (15.45) 16.03 88.37 
 LA 2026 43.65 (7.82) 19.00 75.00 
 MWT 2079 19.36 (5.47) 7.00 43.00 
 FS 1985 0.41 (0.09) 0.10 0.82 
 LVOT max 1745 26.87 (37.98) 1.00 260.00 
 Female 2082 748   
 Prior TE 2082 25   
 AF 2082 167   
 VKA 2082 103   
 NYHA II 1959 772   
 NYHA III,IV 1959 174   
 Vascular disease 1320 15   
 Hypertension 1977 405   
 Diabetes 1319 60   
ATHENS Age 558 46.43 (16.24) 16.00 82.44 
 LA 558 43.65 (6.37) 23.00 65.00 
 MWT 558 18.11 (4.02) 12.00 37.00 
 FS 558 0.40 (0.07) 0.07 0.64 
 LVOT max 558 31.86 (36.18) 2.00 175.00 
 Female 557 165   
 Prior TE 558 8   
 AF 558 75   
 VKA 558 42   
 NYHA II 558 182   
 NYHA III,IV 558 49   
 Vascular disease 558 9   
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 Hypertension 558 148   
 Diabetes 558 37   
BOLOGNA Age 516 50.88 (15.73) 17.16 90.26 
 LA 510 45.48 (8.53) 20.00 85.00 
 MWT 516 20.17 (4.89) 15.00 39.00 
 FS 500 0.41 (0.11) 0.06 0.77 
 LVOT max 516 33.97 (48.08) 4.00 237.00 
 Female 516 184   
 Prior TE 516 5   
 AF 516 79   
 VKA 516 56   
 NYHA II 516 164   
 NYHA III,IV 516 51   
 Vascular disease 516 8   
 Hypertension 516 153   
 Diabetes 516 29   
CORUNA Age 600 56.40 (15.34) 16.72 89.19 
 LA 569 44.38 (7.79) 23.00 73.00 
 MWT 568 20.05 (4.87) 12.00 42.00 
 FS 547 0.41 (0.09) 0.05 0.72 
 LVOT max 311 49.39 (50.31) 2.00 299.00 
 Female 601 223   
 Prior TE 601 16   
 AF 601 102   
 VKA 601 101   
 NYHA II 587 198   
 NYHA III,IV 587 73   
 Vascular disease 601 7   
 Hypertension 601 260   
 Diabetes 563 77   
MADRID Age 242 54.63 (16.52) 16.99 88.32 
 LA 233 44.02 (7.78) 26.00 65.00 
 MWT 237 20.51 (5.36) 7.00 41.00 
 FS 221 0.41 (0.12) 0.08 0.74 
 LVOT max 233 33.11 (41.01) 1.00 250.00 
 Female 242 92   
 Prior TE 242 8   
 AF 237 53   
 VKA 242 53   
 NYHA II 240 58   
 NYHA III,IV 240 17   
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 Vascular disease 241 20   
 Hypertension 242 108   
 Diabetes 242 31   
MURCIA Age 614 53 (17.05) 16.47 90.26 
 LA 594 43.28 (7.69) 23.00 81.00 
 MWT 605 19.06 (5.09) 8.00 43.00 
 FS 534 0.39 (0.10) 0.05 0.78 
 LVOT max 613 35.90 (42.50) 1.00 205.00 
 Female 614 241   
 Prior TE 614 15   
 AF 614 86   
 VKA 614 58   
 NYHA II 609 171   
 NYHA III,IV 609 122   
 Vascular disease 144 19   
 Hypertension 610 278   
 Diabetes 614 45   
NAPLES Age 205 46.81 (15.95) 16.22 83.53 
 LA 137 45.40 (7.81) 25.00 76.00 
 MWT 205 20.32 (4.86) 11.00 40.00 
 FS 13 0.38 (0.17) 0.16 0.78 
 LVOT max 192 30.62 (24.93) 7.00 135.00 
 Female 208 87   
 Prior TE 208 3   
 AF 207 38   
 VKA 205 30   
 NYHA II 146 39   
 NYHA III,IV 146 8   
 Vascular disease 208 11   
 Hypertension 208 62   
 Diabetes 208 14   
 
SD: Standard deviation, n: Number, LA: Left atrial size, MWT: Maximal wall thickness, FS: Fractional shortening, LVOT max: 
maximum LV outflow gradient, TE: thromboembolic event, AF: atrial fibrillation, VKA: Vitamin K antagonist, NYHA: New York 
Heart Association Functional classification,  FH SCD: Family history of sudden cardiac death  
5.3.2. Thromboembolic events during follow-up 
During a follow up period of 28330.6 patient years (median 6.0 years, IQR= 3-9.7) 172 
(3.6%) patients reached the primary endpoint within 10 years from first evaluation (105 
CVA, 53 TIA and 14 peripheral emboli); 107 (2.2%) patients within the first 5 years. The 
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5 and 10 year cumulative incidences were 2.9% (95% CI 2.37%- 3.48%) and 6.4% 
(95% CI 5.42%-7.53%) respectively. The clinical characteristics of patients with and 
without TE are shown in table 13. 
Patients in SR at first evaluation who developed TE during follow up were older (55.0 
years vs 47.5 years; difference in means= 7.5 years; 95% CI= 4.60-10.42), had larger 
LA diameter (46.0 mm vs 43.0 mm; difference in means= 3.0 mm; 95% CI= 1.7-4.32) 
and were more symptomatic (NYHA III, IV) (14.4% vs 9.0%; difference in proportions= 
0.054; 95% CI= 0.0099-0.1181) compared to patients who did not have an event. There 
was also a higher percentage of patients with vascular disease (5.7% vs 2.0%; 
difference in proportions= 0.037; 95% CI= 0.0074-0.0812) in the event cohort (Table 
15). The mean age of patients with and without vascular disease was 62.4 years and 
49.1 years respectively.  
Table 15: Thromboembolic events in patients with sinus rhythm and AF at baseline 
evaluation 
  SR SR AF AF 
 characteristic total mean (SD)/n (%) total mean (SD)/n (%) 
TE no Age 4087 47.49 (16.29) 552 57.87 (13.91) 
 LA 3925 42.99 (7.15) 531 50.03 (8.60) 
 MWT 4047 19.43 (5.26) 547 19.35 (4.51) 
 FS 3719 0.41 (0.09) 475 0.38 (0.11) 
 LVOT max 3502 32.45 (41.48) 516 27.70 (37.09) 
 Female 4090 1436 (35.11) 552 225 (40.76) 
 Prior TE 4091 71 (17.36) 552 0 
 VKA 4089 85 (2.08) 552 323 (58.51) 
 NYHA II 3921 1299 (33.13) 525 219 (41.71) 
 NYHA III,IV 3921 353 (9.00) 525 103 (19.62) 
 Hypertension 3995 1125 (28.16) 540 227 (42.04) 
 Diabetes 3363 214 (6.36) 499 65 (13.03) 
 Syncope 4063 602 (14.82) 541 85 (15.71) 
 FH SCD 3966 957 (24.13) 539 111 (20.60) 
 Vascular disease 2933 58 (1.98) 499 21 (4.21) 
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TE yes Age 124 55.00 (15.48) 48 57.62 (15.20) 
 LA 119 46.00 (7.82) 48 52.35 (8.04) 
 MWT 121 20.38 (4.08) 48 19.23 (4.27) 
 FS 114 0.41 (0.09) 46 0.38 (0.10) 
 LVOT max 101 39.98 (41.33) 44 22.66 (36.00) 
 Female 124 53 (42.74) 48 21 (43.75) 
 Prior TE 124 9 (7.26) 48 0 
 VKA 124 7 (5.64) 48 26 (54.17) 
 NYHA II 118 54 (45.76) 47 11 (23.40) 
 NYHA III,IV 118 17 (14.41) 47 21 (44.68) 
 Hypertension 123 37 (30.08) 48 23 (47.92) 
 Diabetes 108 9 (8.33) 44 5 (11.36) 
 Syncope 124 17 (13.71) 47 6 (12.77) 
 FH SCD 120 32 (26.67) 48 8 (16.67) 
 Vascular disease 106 6 (5.66) 44 4 (9.10) 
 
SD: Standard deviation, n: Number, LA: Left atrial size, MWT: Maximal wall thickness, FS: Fractional shortening, LVOT max: 
maximum LV outflow gradient, TE: thromboembolic event, AF: atrial fibrillation, VKA: Vitamin K antagonist, NYHA: New York 
Heart Association Functional classification, FH SCD: Family history of sudden cardiac death 
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5.3.3. Missing data 
Missing data per variable are described in table 16.  
 
Table 16: Missing data per variable 
 
Predictor n Total % 
AF 6 4,821 0.12 
VKA 3 4,821 0.06 
Prior TE 0 4,821 0 
Sex 1 4,821 0.02 
Age 4 4,821 0.08 
NYHA class 206 4,821 4.27 
MWT 53 4,821 1.1 
LA 194 4,821 4.02 
LVEDD 218 4,821 4.52 
LVESD 452 4,821 9.38 
LVOT max 653 4,821 13.54 
Syncope 43 4,821 0.89 
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FH SCD 142 4,821 2.95 
Hypertension 109 4,821 2.26 
Diabetes 801 4,821 16.61 
Vascular disease 1,233 4,821 25.58 
 
n: Number, AF: atrial fibrillation, VKA: Vitamin K antagonist, TE: thromboembolic event, NYHA: New York Heart Association 
Functional classification, MWT: Maximal wall thickness, LA: Left atrial size, LVEDD: Left ventricular end-diastolic dimension, 
LVESD: left ventricular end-systolic dimension,  LVOT max: maximum LV outflow gradient, FH SCD: Family history of sudden 
cardiac death 
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5.3.4. Model Development 
Univariable analyses are shown in table 17. Only maximal LV wall thickness was found 
to have a non-linear association with TE and so a quadratic term was included as a 
candidate for the final prognostic model. The interaction between AF and age was also 
found to be significant. There were 15 predictors (16 regression coefficients) candidates 
for the final model. 
Age, AF, the interaction between age and AF, TE prior to first evaluation, NYHA class II, 
NYHA class III and IV, LA diameter, vascular disease, maximal LV wall thickness and 
(maximal LV wall thickness)2 were included in the risk model. The estimates of the 
hazard ratios and the corresponding confidence intervals for the risk prediction model 
are shown in table 17. There was no significant centre effect as part of a sensitivity 
analysis (shown in table 18). 
The risk of TE in 5 years for an individual HCM patient can be calculated from the 
following equation: 
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P TE at 5 years = 1 – 0.9999874 
exp (Prognostic Index) 
, 
where prognostic index= 
0.030417476 *age (years) +  2.129977874 *af (yes=1/no=0)  - 0.027069595 *age*af + 1.288557829 * TE 
prior (yes=1/no=0) + 0.224673046 *nyha classII (yes=1/no=0)+  0.728180341 *nyha class III/IV (yes=1/
no=0)+  0.032251831 *la diam (mm) + 0.3735254 *mwt (mm) -0.008324216 *mwt
2 
(mm) + 0.51249279
5 *vascular disease (yes=1/no=0) 
 
Table 17:  Exploratory univariable and multivariable analysis for predictors of 
thromboembolism in HCM  
 
Univariable analysis    Multivariable analysis 
predictor HR p CI   predictor HR p CI 
Sex 1.43 0.02 
1.06 - 
1.93 
  AGE 1.03 <0.001 
1.02 - 
1.04 
AGE10 1.45 <0.001 
1.31 - 
1.60 
  AF 8.41 <0.001 
1.95 - 
36.35 
AF 3 <0.001 
2.15 - 
4.19 
  age_af 0.97 0.03 
0.95 - 
1.00 
prior TE 4.15 <0.001 
2.12 - 
8.13 
  prior TE 3.63 <0.001 
1.81 - 
7.29 
NYHA II 1.61 0.01 
1.14 - 
2.29 
  NYHA II 1.25 0.21 
0.88 - 
1.78 
NYHA III,IV 3.66 <0.001 
2.44 - 
5.48 
  NYHA III, IV 2.07 <0.001 
1.35 - 
3.17 
LA5 1.36 <0.001 
1.24 - 
1.48 
  LA 1.03 <0.001 
1.01 - 
1.05 
MWT 1.01 0.3 
0.99 - 
1.04 
  MWT 1.45 <0.001 
1.12 - 
1.88 
FS 0.22 0.08 
0.04 - 
1.20 
  MWT2 0.99 0.01 
0.99 - 
1.00 
EF 0.3 0.08 
0.08 - 
1.16 
  
Vascular 
disease 
1.67 0.12 
0.88 - 
3.18 
LVEDD 1 0.88 
0.98 - 
1.03  
    
LVESD 1.01 0.29 
0.99 - 
1.04  
    
LVOTmax 1 0.09 
1.00 - 
1.01  
    
Hypertension 1.46 0.02 
1.06 - 
1.99  
    
Diabetes 1.36 0.27 
0.79 - 
2.36  
    Vascular disease 3.2 <0.001 1.68 - 
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6.07 
MWT 1.67 <0.001 
1.29 - 
2.16  
    
MWT2 0.99 <0.001 
0.98 - 
0.99  
     
Age10: Hazard ratio for 10 year increments, VKA: Vitamin K antagonist, AF: atrial fibrillation, TE: thromboembolic event NYHA: 
New York Heart Association Functional classification, LA5: Hazard ratio for left atrial size for 5mm increments, MWT: Maximal 
wall thickness, FS: Fractional shortening, EF: Ejection fraction,  LVEDD: Left ventricular end-diastolic dimension, LVESD: left 
ventricular end-systolic dimension,  LVOT max: maximum LV outflow gradient, HR: Hazard ratio, p: p-value, CI: 95% confidence 
interval, HR MI: Hazard ratio following multiple imputation, p MI: p-value following multiple imputation, CI MI: 95% confidence 
interval following multiple imputation 
MWT and MWT
2
 in the last two rows of the table adjust for MWT and its square term 
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Table 18:  Thromboembolism risk prediction model and sensitivity analysis for centre 
effect 
 
without centre    with centre    
predictor HR p CI HR p CI 
AGE 1.03 <0.001 1.02 - 1.04 1.030 <0.001 1.02 - 1.04 
AF 8.41 <0.001 1.95 - 36.35 8.740 <0.001 2.03 - 37.70 
age_af 0.97 0.030 0.95 - 1.00 0.970 0.030 0.95 - 1.00 
prior TE 3.63 <0.001 1.81 - 7.29 3.600 <0.001 1.78 - 7.28 
NYHA II 1.25 0.210 0.88 - 1.78 1.230 0.250 0.86 - 1.75 
NYHA III, IV 2.07 <0.001 1.35 - 3.17 2.020 <0.001 1.31 - 3.13 
LA 1.03 <0.001 1.01 - 1.05 1.030 <0.001 1.01 - 1.05 
MWT 1.45 <0.001 1.12 - 1.88 1.460 <0.001 1.13 - 1.89 
MWT2 0.99 0.010 0.99 - 1.00 0.990 0.010 0.99 - 1.00 
Vascular 
disease 
1.67 0.120 0.88 - 3.18 1.760 0.100 0.90 - 3.42 
Athens    0.590 0.070 0.34 - 1.03 
Bologna    0.880 0.660 0.50 - 1.55 
Corunña    1.080 0.740 0.70 - 1.65 
Madrid    0.660 0.380 0.26 - 1.67 
Murcia    0.930 0.760 0.56 - 1.53 
Naples    0.730 0.540 0.26 - 2.01 
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AF: atrial fibrillation, age_af: interaction between age and AF, TE: thromboembolic event, NYHA: New York Heart Association 
Functional classification, LA: Left atrial size, MWT: Maximal wall thickness, HR: Hazard ratio, p: p-value, CI: 95% confidence 
interval. Age: Hazard ratio for 10 year increments, LA: Hazard ratio for left atrial size for 5mm increments. 
From Guttmann et al (2015) 272 
5.3.5. Model validation 
Bootstrapping showed a good calibration slope of 0.91 (95% CI: 0.74, 1.08). Figure 11 
illustrates a good agreement between the observed and predicted risk at exploratory 
thresholds of thromboembolic risk at 5 years. The C-index was 0.75 (95% CI: 0.70, 
0.80) and the D-statistic was 1.30 (95% CI: 1.05, 1.56) indicating good discrimination. 
 
Figure 11: Agreement between observed and predicted risk of at exploratory 
thresholds of thromboembolic risk at 5 years  
 
Group 1: 2464 patients, Group 2: 1274, Group 3: 696, Group 4: 387 
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5.3.6. Comparison with conventional stroke prediction models 
222 patients with complete data and AF not treated with VKA at baseline evaluation; of 
these, 61 (27.5%) had a CHA2DS2-VASc score of 0 and 19 (8.6%) a score between 4 
and 6. No patient had a score of 7 to 9. Table 19 presents the prevalence of TE in 
patients according to CHA2DS2-VASc score. Figure 12 displays the cumulative 
incidence of TE according to CHA2DS2-VASc score groups and according to 5 year risk 
prediction model. 
Table 19: Prevalence of thromboembolism according to CHA2DS2-VASc score in 
HCM patients with AF not treated with VKA. 
  
CHA2DS2-VASc Score TE no, n (%) TE yes, n (%)  
0 55 (90.16%) 6 (9.84%) 
1 69 (95.83%) 3 (4.17%) 
2 37 (88.10%) 5 (11.90%) 
3 26 (92.86%) 2 (7.14%) 
4 11 (73.33%) 4 (26.67%) 
5 2 (66.67%) 1 (33.33%) 
6 1 (100%) 0 (0%) 
Total 201 (90.54%) 21 (9.46%) 
 
TE: Thromboembolic events, n: Number 
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Figure 12: Kaplan-Meier failure estimates for cumulative incidence of TE. The left graph 
displays the cumulative incidence of TE according to CHA2DS2-VASc score groups 
(Low=0; 61 patients, Intermediate=1; 72 patients, High>2; 89 patients). The right graph 
displays the cumulative incidence of TE according to 5 year risk prediction model (Low= 
0%-1.5%; 1643 patients, Medium-Low=1.5%-3%; 887 patients, Medium-High=3%-5%; 
494 patients, High>5%; 287 patients) 
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4.3.7. Relationship of LA size to risk of thromboembolic events 
Figure 13 shows the relationship between LA size and 5 year risk of TE. There appears 
to be a linear relationship up to about 45-50mm at which point the risk of TE rises 
exponentially with increasing LA diameter. In the cohort of patients in SR at first 
evaluation with a LA diameter more than 50 mm, the prevalence of a thromboembolic 
event was 4.7% (table 20). Patients with an event in this group were older (55.8 years 
vs 50.1 years) as compared to patients who did not experience an event. Patients in AF 
who did not develop a thromboembolic event had a smaller LA diameter (50.0 mm vs 
52.3 mm) and were less symptomatic (NYHA III, IV) (19.6% vs 44.7%) compared to 
patients with an event. The characteristics are displayed in table 15. 
 
 
 
106 
 
Table 20: Thromboembolic events in patients with sinus rhythm with LA>45 and sinus 
rhythm LA>50 at baseline evaluation 
  SR, 
>45 
SR, >45 SR, 
>50 
SR, >50 
 variable total mean (SD)/n (%) total mean (SD)/n (%) 
TE no Age 1499 50.45 (14.94) 728 50.15 (15.08) 
 LA 1336 50.78 (4.40) 565 54.80 (3.86) 
 MWT 1478 20.72 (5.19) 710 21.10 (5.37) 
 FS 1291 0.41 (0.10) 567 0.41 (0.11) 
 LVOT max 1275 42.68 (46.60) 608 45.12 (47.95) 
 Female 1502 444 (29.56) 731 193 (26.40) 
 Prior TE 1502 34 (2.26) 731 14 (1.92) 
 VKA 1500 62 (4.13) 729 43 (5.90) 
 NYHA II 1434 526 (36.68) 692 245 (35.40) 
 NYHA III, IV 1434 192 (13.39) 692 118 (17.05) 
 Hypertension 1462 465 (31.81) 711 227 (31.93) 
 Diabetes 1223 102 (8.34) 593 48 (8.09) 
 Syncope 1494 232 (15.53) 725 110 (15.17) 
 FH SCD 1461 330 (22.59) 708 153 (21.61) 
 Vascular disease 1114 22 (1.97) 543 9 (1.66) 
TE yes Age 62 56.20 (12.35) 34 55.75 (11.94) 
 LA 57 52.12 (6.08) 29 56.03 (6.27) 
 MWT 59 20.92 (4.35) 32 21.97 (4.98) 
 FS 56 0.42 (0.09) 30 0.41 (0.10) 
 LVOT max 51 42.96 (41.55) 29 41.76 (32.80) 
 Female 62 24 (38.71) 34 11 (32.35) 
 Prior TE 62 6 (9.68) 34 4 (11.76) 
 VKA 62 6 (9.68) 34 5 (14.71) 
 NYHA II 59 28 (47.46) 31 12 (38.71) 
 NYHA III, IV 59 8 (13.56) 31 7 (22.58) 
 Hypertension 61 19 (31.15) 34 11 (32.35) 
 Diabetes 55 6 (10.01) 27 2 (7.41) 
 Syncope 62 9 (14.52) 34 5 (14.71) 
 FH SCD 59 14 (23.73) 32 9 (28.13) 
 Vascular disease 55 5 (9.10) 28 4 (14.29) 
 
SD: Standard deviation, n: Number, LA: Left atrial size, MWT: Maximal wall thickness, FS: Fractional shortening, LVOT max: 
maximum LV outflow gradient, TE: thromboembolic event, AF: atrial fibrillation, VKA: Vitamin K antagonist, NYHA: New York 
Heart Association Functional classification, FH SCD: Family history of sudden cardiac death 
From Guttmann et al (2015) 272 
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Figure 13: Relationship of LA size with risk of thromboembolism 
  
 
From Guttmann et al (2015) 272 
5.4. Discussion 
In this study we present the first validated model for TE prediction in a diverse 
population of adult patients with HCM. The study confirms the high risk of TE in patients 
with AF and the strong association between atrial size and thromboembolic risk 16;177;270. 
It also demonstrates an association with several other patient characteristics including 
age, heart failure symptoms, and maximal LV wall thickness and, for the first time in this 
population, vascular disease. 
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5.4.1. CHA2DS2-VASc score in HCM 
Clinical guidelines recommend the CHA2DS2-VASc score as means of stratifying 
patients with non-valvular AF for antithrombotic prophylaxis 262;263;281. We show that this 
score has a relatively low predictive accuracy in patients with HCM that is probably 
explained by the lower prevalence of vascular risk factors. These data support recent 
consensus guidelines from the ESC that advise against the use of the CHA2DS2-VASc 
score in patients with HCM 3. 
5.4.2. Implications for patients in SR 
The risk of TE risk in patients who are in SR has not been examined in detail previously. 
Risk factors for TE in this group included advanced age, heart failure symptoms, 
increased LA diameter and vascular disease. While this study does not prove that 
patients in SR who have a high estimated risk of TE benefit from anticoagulation prior to 
the development of AF, it does support recent recommendations for frequent 
ambulatory ECG monitoring in patients with LA enlargement 3. Irrespective of atrial 
rhythm, clinicians should also be alert to conventional vascular risk factors and treat 
them appropriately. 
5.4.3. Limitations 
The patient population in this study is large and diverse but the model should only be 
used in patients with similar characteristics. It is not validated in paediatric patients (less 
than 16) and in patients with metabolic or syndromic disorders. 
A prospective external validation in a different cohort of patients would be ideal.  
Ethnicity may have influenced the findings. Data on this was not available in this cohort. 
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The model includes patients who are treated with VKA according to current guidelines. 
Excluding these patients would exclude high risk patients and limit the statistical 
analysis. 
5.5. Conclusions 
The study shows that the risk of TE in patients with HCM can be identified using a small 
number of simple clinical features. LA size, in particular, should be monitored closely 
and the assessment and treatment of conventional vascular risk factors should be 
routine practice in older patients. The CHA2DS2-VASc score does not appear to 
correlate well with the clinical outcome in patients with HCM and should not be used to 
assess TE risk in this population. 
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6 Outcome of anticoagulation and 
antiarrhythmic therapy in patients with HCM 
 
6.1. Aims 
 
AF and TE are common complications of the disease and are associated with adverse 
clinical outcomes and reduced survival 177;179;202;232;245;270. Current ESC and ACCF/AHA 
guidelines recommend anticoagulation in all patients with HCM and AF 262;263;273;282;283. 
The efficacy of vitamin K antagonists has not been investigated in patients with HCM 
and AF in randomised controlled trials. Stroke was less common in anticoagulated 
patients as compared to antiplatelet therapy in two observational studies 176;177. Further 
two small studies compared TE events in patients on and off warfarin 231;233 
The primary aim of this study was to assess the outcome of therapy with vitamin K 
antagonists (VKA) in patients with AF. The bleeding risk in patients with HCM was 
assessed using the HAS-BLED score in an exploratory analysis. Exploratory analyses 
were also performed to investigate the efficacy of antiarrhythmic therapy in the 
prevention of AF. 
 
6.2. Methods 
  
6.2.1. Study design and overview 
Data from a retrospective, multicentre longitudinal cohort – the Hypertrophic 
Cardiomyopathy Outcome Investigators (www.HCMRisk.org) 167 – were used in the 
development of the prognostic model.  
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The study conforms to the principles of the Helsinki declaration. The sponsors of this 
study did not have a role in study design, data collection, analysis, and interpretation. 
O.G., M.P., R.O., and P.E. had access to all data and final responsibility to submit the 
article. The authors from each centre guarantee the integrity of data from their 
institution. All investigators have agreed to the article as written. 
 
6.2.2. Study population and participating centres 
The study cohort has been described in detail in Chapter 4 and 5. 
Patients with a history of AF that had experienced TE prior to first evaluation at the 
centre were also excluded from the analysis. 
  
6.2.3. Patient assessment and data collection 
Patients were reviewed every 6–12 months or earlier if there was a change in 
symptoms. All patients underwent clinical assessment, pedigree analysis, physical 
examination, resting and ambulatory electrocardiography and transthoracic 
echocardiography. Each centre collected data independently using the same 
methodology. 
6.2.4. Clinical outcomes 
The primary outcome was a thromboembolic event defined as a composite of 
cerebrovascular accident (CVA), transient ischaemic attack (TIA) or systemic peripheral 
embolus as defined in the CHA2DS2-VASc score. CVA was defined as a focal 
neurologic deficit of sudden onset as diagnosed by a neurologist, lasting more than 24h 
and caused by ischaemia. TIA was defined as a focal neurologic deficit of sudden onset 
as diagnosed by a neurologist, lasting less than 24 h. Peripheral embolism was defined 
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as TE outside the brain, heart, eyes, and lungs 274. For the analysis of the effect of 
antiarrhythmic therapy on the development of AF The outcome of interest was atrial 
fibrillation, which was defined as paroxysmal, permanent or persistent AF detected on 
ECG, Holter monitoring or device interrogation. 
6.2.5. Clinical outcome of anticoagulation in patients with AF 
The incidence of TE in patients with AF who and were not treated with anticoagulants 
was investigated using an intention to treat analysis.  If a patient received treatment with 
VKA at any time prior to the event it was assumed that they continued on this 
medication for the duration of the study. The numbers of patients with and without TE 
that did or did not receive VKA were compared. The absolute risk reduction (ARR) and 
number needed to treat (NNT) were calculated for patients in AF at an exploratory 
threshold of 4% risk of thromboembolic event over 5 years. 
 
6.2.6. HAS-BLED score in patients with HCM 
To assess the bleeding risk of our population, we calculated the HAS-BLED score in 
HCM patients with AF 284.  
6.2.7. Clinical outcome of antiarrhythmic therapy 
 
An intention to treat analysis was used to investigate clinical outcomes in patients 
receiving β-adrenoreceptor blockers, non-dihydropyridine calcium channel antagonists, 
disopyramide and amiodarone. If a patient received treatment at any time prior to the 
event it was assumed that they continued on this medication until the endpoint of the 
study was reached or the end of follow up. The effect on development of AF was 
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investigated. The total number of patients in the AF group and SR groups on and off 
medication were compared and assessed for statistical significance. 
 
6.3. Results 
6.3.1. Baseline clinical characteristics  
During the study period 5104 patients were evaluated, of whom 197 were seen only 
once for baseline evaluation and were excluded from the analysis of relation between 
anticoagulation and TE risk in patients with AF. Eighty six patients with a history of AF 
and TE prior to first evaluation were also excluded. The final study cohort for this 
analysis consisted of the remaining 4821 patients and the baseline clinical 
characteristics are shown in table 13.  
For the analysis of the clinical outcomes in patients receiving antiarrhythmic therapy of 
the 5104 patients, 197 patients, who were only seen once at baseline evaluation and an 
additional 659 patients with AF prior to first evaluation were excluded for the analysis of 
AF events. The final study cohort therefore consisted of 4248 patients (baseline clinical 
characteristics are shown in table 7). 
6.3.2. Relation between anticoagulation and TE risk in patients with AF 
Table 21 presents an unadjusted exploratory analysis of the prevalence of TE over 10 
years in patients with AF at first evaluation that did or did not receive VKA during the 
follow up period prior to TE; 12.4% of those not receiving VKA and 6.8% of patients of 
those who were receiving anticoagulation had a thromboembolic event. This 
corresponds to a relative risk reduction of 54.8% (CI 0.31-0.97, p=0.037) with VKA 
treatment. Figure 14 displays the Kaplan Meier curves comparing VKA and non VKA 
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groups. The absolute risk reduction (ARR) and number needed to treat (NNT) for 
patients in AF at an exploratory threshold of 4% risk of thromboembolic event over 5 
years is 13% (95% CI, 2.1%-24%) and 7.7 respectively. These results should be 
interpreted with caution as the small numbers meant that a standard multivariable 
model adjusting for warfarin and the rest of the predictors was not appropriate. Instead 
we fitted a multivariable model as a sensitivity analysis using Lasso regression, a 
penalised regression method suitable for datasets with few events 285. In this fully 
adjusted analysis, warfarin maintained its protective effect (results not shown). We also 
used propensity score analysis to further explore the indication for the effect of VKA on 
stroke. The propensity score for each patient was calculated as the predicted probability 
of receiving VKA. It is clinical practice in the participating centres to consider therapy 
with VKA in patients with significantly enlarged LA diameter. Indeed LA was the 
strongest balancing factor in the propensity score model to identify treatment allocation 
variables, while older age, history of diabetes and smaller fractional shortening were 
also associated with higher probability of receiving VKA. Subsequently a Cox regression 
model for the time to TE adjusting for VKA and the propensity score 286, showed that 
VKA maintained its protective effect (HR=0.41; 95% CI=(0.22-0.76)). 
Table 21: Outcome of treatment with VKA prior to event in patients with AF at 
baseline evaluation with and without thromboembolism 
 
AF VKA no TE % TE % 
 no 113 87.60 16 12.40 
 yes 439 93.21 32 6.79 
 Total 552 92.00 48 8.00 
 
AF: Atrial fibrillation, VKA: Vitamin K antagonist, TE: Thromboembolic events 
From Guttmann et al (2015) 272 
Figure 14: Kaplan-Meier failure estimates comparing thromboembolic events in VKA 
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and non VKA groups 
 
 
 
From Guttmann et al (2015) 272 
6.3.3. Bleeding risk in patients with HCM 
 
Calculation of the HAS-BLED score in a population of 536 patients with HCM and AF 
revealed a score of 0-2 in 500 patients (93.3%) with a score of 3-5 in 36 patients (6.7%). 
A score of ≥3 indicates ‘high risk’, leading to some caution and regular review of the 
patient following the initiation of VKA therapy (table 22) 262;263;284.  
 
 
 
 
Table 22: Number of patients with HCM and AF and corresponding HASBLED score 
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HASBLED score n % 
0 217 36.17 
1 179 29.83 
2 104 17.33 
3 31 5.17 
4 4 0.67 
5 1 0.17 
 
n: Number 
6.3.4. Clinical outcome of antiarrhythmic therapy 
 
The Kaplan-Meier survival curves for the development of AF over a ten year follow up 
period by treatment group are displayed in figure 15. To minimise the biasing effect of 
the intention to treat analysis the hazard ratios were also calculated for a follow up 
period of 1 year (table 23). In view of the HR of 2.07 of amiodarone the number of 
patients on amiodarone in the absence of a diagnosis of AF at first evaluation was also 
determined. Out of 311 patients receiving amiodarone at first evaluation only 23 had a 
prior diagnosis of AF. The Kaplan-Meier survival estimates for a follow up of one year 
for therapy with calcium channel blockers and disopyramide showed a trend towards a 
reduction in AF occurrence (figure 16).   
 
 
 
 
 
 
Figure 15: Kaplan Meier survival estimates for development of AF over ten year 
follow up period in treatment and non-treatment group (beta-blocker, Ca-
channel antagonist, disopyramide and amiodarone) 
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Table 23:  1 year hazard ratios for development of AF according to medication 
 
Medication HR SE p CI 
Beta-blocker 1.14 0.18 0.41 0.83-1.55 
Ca-antagonist 0.80 0.20 0.36 0.49-1.29 
amiodarone 2.17 0.47 <0.001 1.33-3.21 
disopyramide 0.96 0.35 0.01 0.47-1.95 
HR: Hazard ratio, p: p-value, CI: 95% confidence interval, SE: Standard error 
 
 
 
 
 
 
Figure 16: Kaplan Meier survival estimates for development of AF over one year 
follow up period in treatment and non-treatment group (Ca-channel 
antagonist, left; disopyramide, right) 
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6.4. Discussion 
6.4.1. Clinical outcome of anticoagulation in HCM patients 
 
There are no prospective randomised trials of any therapy for AF in HCM including 
anticoagulation and only a very small number of observational studies comparing VKA 
with antiplatelet drugs 177;231;233;270.  In this study, an intention to treat analysis of VKA 
demonstrated a relative risk reduction for TE of 54.8% in anticoagulated patients who 
had AF at baseline evaluation, supporting current international guidelines for the use of 
VKA in HCM 3;273. The intention to treat analysis was felt to be the most appropriate way 
of analysing data gathered retrospectively over such a long period, although we 
acknowledge that this methodology may have led to the inclusion of patients who had 
discontinued VKA or whose INR was sub-therapeutic at the time of a thromboembolic 
event. Current guidelines recommend anticoagulation with CHA2DS2-VASc score of 1 or 
above in patients with non-valvular AF, which corresponds to an adjusted stroke rate of 
1.3% per year 262;263;274. The absolute risk reduction (ARR) and number needed to treat 
(NNT) for patients in AF at an exploratory threshold of 4% risk of thromboembolic event 
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over 5 years are 13% and 7.7 respectively. The NNT in non-valvular AF is 12 for 
secondary 37 for primary prevention 287.  
6.4.2. Use of HAS-BLED score in HCM 
 
The use of the HAS-BLED score to assess the bleeding risk with VKA revealed a high 
risk value in only 6.8% of the cohort, reflecting the fact that HCM cohorts are generally 
younger with less conventional risk factors for bleeding. 
6.4.3. Effect of antiarrhythmic on AF development 
 
There are no prospective randomised trials of medical therapy for AF in HCM and only a 
very small number of observational studies assessing efficacy of antiarrhythmic therapy 
in maintenance of sinus rhythm or suppression of supraventricular tachycardia 288;289.  In 
this study, an intention to treat analysis of β-adrenoreceptor blockers, calcium channel 
antagonists and disopyramide demonstrated no significant effect of these therapies in 
prevention of AF. The retrospective nature of the analysis means that interpretation of 
these findings should be cautious; however, we sought to minimise the biasing effect of 
this analysis by also calculating the hazard ratios for a follow up period of 1 year which 
demonstrated findings consistent with those at 10 years.  
Contrary to expectations, amiodarone therapy appeared to have detrimental effect on 
the development of AF with a hazard ratio of 2.07. However, a large proportion of 
patients on amiodarone did not have a history of AF at first evaluation and we speculate 
that the apparent negative effect of the drug might be explained by its use to prevent 
sudden cardiac death in patients with non-sustained ventricular tachycardia (NSVT) as 
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this group of patients may have more myocardial fibrosis and advanced disease and 
thus be more prone to AF 290-292. 
6.4.4. Clinical implications 
 
In this study, an intention to treat analysis of VKA demonstrated a relative risk reduction 
for TE in anticoagulated patients who had AF, supporting current international 
guidelines for the use of VKA in HCM 3;273. In spite of its limitations, the intention to treat 
analysis for antiarrhythmic therapy suggests that rhythm control strategies for patients 
with AF and HCM are suboptimal and require revaluation in prospective randomised 
trials. 
 
6.5. Conclusions 
Exploratory analyses show for the first time evidence for a reduction of TE with VKA 
treatment. HCM patients appear to be a good target for therapy with anticoagulation 
with less conventional risk factors for bleeding. There was no evidence for a beneficial 
effect of antiarrhythmic therapy on the development of atrial arrhythmia. 
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7 CONCLUSIONS 
7.1 Significance of AF and thromboembolism in HCM 
 
It has been clear since the early descriptions of hypertrophic cardiomyopathy that AF and 
thromboembolism are common 15. In this thesis I have shown how important AF and 
stroke are when looking after patients with HCM. A large proportion of patients with AF 
suffer from symptoms secondary to AF and the related mortality is very high. The analyses 
shown here represent the most comprehensive review of current literature in this area with 
a meta-analysis and systematic analysis of a large population of patients with HCM. I 
have shown that previous studies on AF and thromboembolism in HCM are very 
heterogeneous in terms of cohort size, definitions of disease and follow up durations. In 
addition I have collated, assessed and investigated the largest population of patients 
with HCM to date from seven centres in Europe. The analyses reveal that about a fifth 
of patients are affected by AF and that a very large proportion of these patients will 
suffer from thromboembolic complications.  
AF affects 1–2% of the general population and the prevalence of AF increases with age, 
from 0.5% at 40–50 years, to 5–15% at 80 years 293;294. AF and stroke in HCM are 
different though. As seen in this work the patient population are younger with a mean 
age of 49 years. A large proportion of these patients is asymptomatic and also has a 
low vascular risk factor profile, which can at least partially be explained by the mean 
age of the population.  
Nevertheless the incidence and prevalence of thromboembolism is striking and the 
implication in terms of morbidity and mortality enormous. I have demonstrated the 
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impact of AF in these patients by demonstrating the statistically significant difference in 
incidence of cardiovascular death comparing patients in the sinus rhythm and in AF. 
7.2 Predictors of AF and thromboembolism  
 
The good news is that I have shown that clinicians can predict AF and stroke by using 
simple readily available clinical parameters such as age, sex, LA dimension, thickness 
of the left ventricular wall and symptomatic status such as NYHA class and general risk 
factors such as hypertension and vascular disease. Again these risk factors are at least 
partially different from the general population and reflect the difference in the disease 
processes in HCM as compared to the general population. 
This is underlined by the fact that I have shown that the CHA2DS2-VASc score, which is 
used as a means of stratifying patients with non-valvular AF for antithrombotic 
prophylaxis, has a relatively low predictive accuracy in patients with HCM. This is 
probably explained by the lower prevalence of vascular risk factors 262;263;281.  The data 
shows that this score performs poorly in patients with HCM and that it should not be 
used to assess TE risk in this population.  
Instead I was able to develop a risk stratification model to predict an individual patient’s 
risk of thromboembolism over 5 years using these clinical parameters. The model 
revealed satisfactory performance and will guide management of these patients and 
decision making with regards to therapy with anticoagulation. 
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7.3 Medical therapy in patients with HCM 
 
It is not enough to predict a thromboembolic event. Clinicians must be able to treat 
patients satisfactorily and avoid this complication. Using an intention to treat analysis I 
was able to provide exploratory analyses on anticoagulation that show for the first time 
evidence for a reduction of TE with VKA treatment in a unique and large cohort of 
patients. VKA treatment was associated with a significant relative risk reduction in HCM 
patients with AF. 
Medical therapy has not proven to be effective in preventing or at least delaying the 
development of AF in HCM in the first place. To investigate this, I utilised an intention to 
treat analysis to assess the use of commonly used antiarrhythmic drugs in this disease, 
i.e. β-adrenoreceptor blockers, calcium channel antagonists, disopyramide and 
amiodarone. This did not demonstrate evidence for the efficacy of antiarrhythmic 
therapy in development of atrial fibrillation.  
7.4 Future directions 
 
There are several research questions that have become clear and evident to me during 
the course of this project. A prospective study on AF and thromboembolism in HCM 
patient could be an idea for the future. Setting this up could prove to be very 
challenging. This is in view of the event rate and therefore a very long follow up time to 
achieve a meaningful prognostic model for statistical analysis. There are some clinical 
parameters that would be most interesting to additionally include at that point. LA 
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volume or area and LV mass would be some of these. Similarly cardiac MR data could 
then be incorporated and could also include assessment of atrial fibrosis. Arterial blood 
pressure as a continuous variable would also be of some interest in determining the 
relationship with AF. To be more certain that of the diagnosis of HCM, it would also 
have been helpful to collect the distribution of hypertrophy.  
Diagnosing AF and thromboembolism especially transient ischaemic attacks can be 
challenging in clinical practice. This is especially the case in retrospective data 
collection. A prospective study could potentially improve the system of detecting AF and 
thromboembolism and would therefore improve the power of the statistical analysis. 
Another topic for future assessment is medical therapy. Many patients remain hesitant 
with regards to treatment with vitamin K antagonists but prefer therapy with newer 
agents. Due to current guidelines randomised controlled studies on anticoagulation in 
HCM are unlikely in the future, but investigating vitamin K antagonists versus novel 
agents of anticoagulation would be a desired approach for a randomised control studies 
in this area.  
My work did not demonstrate evidence for the efficacy of antiarrhythmic therapy in 
development of atrial arrhythmia, but there is a clear lack of randomised controlled trials 
in this area.  If medical therapy turns out to not be successful in preventing the 
recurrence or the development of atrial fibrillation in the first place substrate modification 
would be an interesting field of work for the future. Data on electrophysiological ablative 
therapy is limited but reveals suboptimal results to date. Long term maintenance of 
sinus rhythm is achieved in no more than 50-60% of patients 187;248-250. Early treatment 
of LVOTO even in the absence of symptoms is another pathway worth considering in 
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this respect as well. The rational for this approach would be to intervene early prior to 
development of atrial dilatation and scarring.  
A large proportion of patients with HCM have enlarged atrial dimensions but no clinical 
evidence of atrial fibrillation when reviewed in clinic. These patients are at high risk of 
developing of AF and therefore thromboembolism as I have shown in this thesis. 
Addressing this important question of the efficacy and risk of aggressive and early use 
of anticoagulation in patients is therefore crucial. Some groups also advocate the use of 
aspirin in these patients in the absence of atrial fibrillation. There is no evidence 
available to support this approach. A study into the effectiveness of thromboembolic 
prophylaxis of this approach would be of high clinical relevance. 
Finally inclusion of further centres especially centres from outside of Europe for external 
validation of the proposed prognostic model is necessary and would be very useful. 
Further data from centres outside of Europe to ensure availability of data from further 
ethnic groups is crucial. 
7.5 Limitations 
 
There are some limitations of this work that I would like to point out. All the studies in 
this thesis were carried out on a cohort of HCM patients based at seven collaborating 
centres in Italy, Spain, Greece and the UK. Referral bias is therefore an important 
limitation to consider. The collaborating centres are mostly tertiary referral centres. More 
severely affected and therefore the referred patients might have therefore been included 
into the study. It is also important to note that some of the associations identified are too 
weak to be predictive. 
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Some of the limitations are due to retrospective nature of the data collection. This meant 
a limitation of clinical parameters that could be examined, which are those that were 
historically collected by investigators at the international centres. The left atrial area or 
volume for example as a measure of LA size would have been preferable rather than 
left atrial diameter. The same is true for maximal wall thickness of a single myocardial 
segment rather than the total LV mass. A prospective external validation in a different 
cohort of patients would hence be ideal. 
The inter-observer variability data for assessment of LA size and the lack of data on 
bleeding rates are also an important limitations.  
Ethnicity may have influenced the findings. Data on this were not available in this 
cohort. 
A further important point is that the patient population in this study is large and diverse 
but the model should only be used in patients with similar characteristics. It is not 
validated in paediatric patients (less than 16) and in patients with metabolic or 
syndromic disorders. 
In this study, an intention to treat analysis was utilised in investigating the effect of 
vitamin K antagonists and antiarrhythmic medication. The intention to treat analysis was 
felt to be the most appropriate way of analysing data gathered retrospectively over such 
a long period. This may have led to the inclusion of patients who had discontinued 
medication or whose INR was sub-therapeutic at the time of a thromboembolic event. 
AF in HCM can be difficult to diagnose especially in patients with paroxysmal episodes 
of arrhythmia. A similar difficulty applies to the detection of TIA in clinical practice.  This 
is a limitation common to all studies of AF and thromboembolism. A prospective study 
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with these as primary outcomes would be a way around this and has been discussed 
above. 
The prognostic model includes patients who are treated with VKA according to current 
guidelines. Excluding these patients would exclude high risk patients and limit the 
statistical analysis. 
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